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1. GENEHAL INTRODUCTION 
Recent advances in understanding the biology amd therapy of leukemia and 
lymphoma have a considerable impact on the survival in this 
heterogeneous group of diseases. Long-term disease free survival rates 
(>3 years) of 10-60% for patients with acute leukemia depending on age 
are now attained in patients who receive chemotherapy [1]. Nevertheless, 
many relapses occur and in adults the survival beyond 5 years is still 
low [2]. Most patients who fail to respond to primary chemotherapy have 
a very poor prognosis with this conventional therapy [3,4]. The anti­
leukemic effect of chemotherapy and radiation is related to the dose 
which is limited by concomitant myelosuppression. The property of bone 
marrow cells to home in the bone marrow compartment allows a 
repopulation and restoration of the hematopoiesis after the intravenous 
infusion of bone marrow cells. Infusion of donor or autologous bone 
marrow cells makes feasible treatment with supralethal doses of chemo-
radiotherapy and to rescue the patient with bone marrow transplantation 
(BMT). Presently BMT offers the best chance of long-term disease free 
survival in acute leukemias and highly malignant lymphomas [1,5]. 
Allogeneic bone marrow transplantation 
The first bone marrow tranplantation was performed in animals by Lorenz 
and colleagues [6]. They discovered that supralethally irradiated mice 
could be fully reconstituted hematologically and immunologically by 
intravenous infusion of syngeneic bone marrow. Investigators in the late 
fifties demonstrated that allogeneic bone marrow transplantation could 
also be successful if the recipient strains of mice had been matched 
for the major histocompatibility complex (MHO antigens [7,8]. After the 
identification of the human MHC (HLA) in 1968, the first successful ΒΜΓ 
was performed with a HLA-identical sibling donor bone marrow [9]. Since 
1970 BMT is increasingly used to treat severe immune deficiencies, 
aplastic anemia and leukemias. At present, world wide more than 22,000 
patients have been treated with allogeneic BMT [10]. However, 
opportunistic infections, interstitial pneumonitis, graft-versus-host 
disease (GVHD), graft rejection and leukemic relapse remain obstacles to 
the success of ΒΜΓ. GVHD is one of the major problems. Moderate to 
severe acute GVHD occurs in 30-70% of HLA-identical recipients with a 
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fatal outcome in approximately 50% of the severely affected patients 
despite posttransplant treatment with immunosuppressive drugs such as 
cyclosporin A and methotrexate [11,12,13]. GVHD is primarily mediated by 
immunocompetent lymphocytes present in the graft [14,15]. Ex vivo 
elimination of Τ cells from the marrow graft improves the clinical 
outcome of BMT by causing a reduction of the incidence and the severity 
of GVHD [16-18]. In this regard, τ cell depletion has been a major 
advance. Unfortunately, elimination of high numbers of Τ cells results 
in a delayed bone marrow reconstitution, or even failure of engraftment 
or late graft rejection. Graft failure, largely due to immunologic 
rejection, increases from <1% with unmodified bone marrow grafts to 
approximately 15% with grafts of τ cell depleted bone marrow [17,19,20]. 
In those cases where bone marrow grafting was used for the treatment of 
leukemia, the incidence of relapse appears significantly increased after 
transplantation of a Τ cell depleted graft [17]. Data from experiments 
in animals suggest that allogeneic BMT confers a graft-versus-leukemia 
(GVL) effect mediated by Τ cells that prevent leukemia relapse [21,22]. 
Though, it is unknown whether a similar phenomenon applies to man, data 
of relapse rates of 60% in identical twin BMT (syngeneic BMT), in which 
in contrast to allogeneic BMT no differences exist in the minor 
histocompatibility antigens, suggest the existence of GVL effect in man 
[23]. If it would be possible to eliminate Τ cell subpopulations 
responsible for the GVHD in the bone marrow, without simultaneous 
depletion of those cells responsible for GVL effect, an improvement of 
the clinical outcome of allogeneic BMT may be expected. 
More than 70% of the patients who might benefit from a BMT, lack a 
HLA-compatible sibling donor. Transplant-related complications such as 
GVHD, graft rejection and infections due to the postgraft 
immunodeficiency, increase the mortality after BMT and limit the 
applicability to younger patients (<45 years). Therefore, allogeneic BMT 
remains restricted to approximately 15% of patients with acute leukemia 
and even a lower percentage of patients with chronic leukemia or 
lymphoma [24]. 
Autologous bone marrow transplantation 
Autologous BMT (ABMT), in which the patient acts as his own marrow 
donor, may circumvent several drawbacks of allogeneic BOT. GVHD and its 
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related complications do not occur and the immunodeficiency is less 
profound, but malignant cells may be present in the graft and the GVL 
effect is absent [25]. Nevertheless the clinical application of АИТГ 
increases steadily [26]. Though ΑΒΜΓ has obvious advantages for patients 
in whom conventional therapy has failed [27,28], relapse rate is higher 
than in allogeneic ΒΜΓ [25,29]. This is partly due to the absence of 
GVHD and GVL effect as was concluded in a study comparing data of 
allogeneic and syngeneic BMT [23]. Moreover, the contaminating leukemic 
cells in the reinfused autologous bone marrow may contribute to the 
increased incidence of relapse. The ability to "purge" marrow 
from malignant cells may decrease the number of relapses after ABMT. 
2. APPROACHES FOR THE ЕЫКЩАТІЩ OF NORMAL OR MALIGNANT Τ CELLS FROM 
BONE MARROW 
In the last few years many methods have been developed to eliminate Τ 
cells from bone marrow. Methods that result in a partial depletion of τ 
cells, such as counterflow centrifugation [18] or rosetting with sheep 
erythrocytes followed by agglutination with soybean agglutinin [30], 
have been applied successfully in allogeneic BMT. However, only those 
methods which achieve a specific and complete elimination of malignant Τ 
cells are suitable for purging of autologous bone marrow and can be used 
for selective elimination of Τ cell subpopulations from donor bone 
marrow, cytostatic agents such as Asta Ζ or 4-hydroperoxycyclophospha-
mide have been used for this purpose, albeit with substantial loss of 
hematopoietic progenitor cells [31,32]. With the development of 
hybridoma technology by Kohier and Milstein [33] it became possible to 
produce specific monoclonal antibodies (MoAbs) directed against 
differentiation antigens or specific tumor antigens expressed on normal 
or malignant cells. MoAbs as such are not toxic to cells. In combination 
with complement, however, cells can be killed effectively and an 
elimination of 3- to 4-logs can be achieved [34-36]. Although the use of 
MoAb with complement is an attractive concept, a number of problems can 
arise when applied to human bone marrow. Firstly, not all MoAbs fix 
complement, and more importantly most MoAbs do not fix human complement 
which necessitates the use of nonspecific xenogeneic complement sources 
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such as rabbit serum. Secondly, complement activity present in rabbit 
sera displays great batch variations. Thirdly, high cell number, 
erythrocytes and unsubstituted cell surface sialic acid residues can 
activate complement resulting in an undesired complement consumption and 
a decreased complement-mediated killing [37]. Fourthly, lysed cells 
cause clumping and are difficult to remove from the cell suspension. 
Finally, fragments of the complement cascade are profound immuno-
regulators with unknown effects on hematopoiesis. 
Approximately 80 years ago Paul Ehrlich put forward the original 
idea of the "magic bullet", a molecule consisting of a toxic compound 
attached to an antibody. This approach may circumvent the problems with 
complement. Many drugs [38,39,62] and radioisotopes [40] have 
been conjugated with MoAbs to increase their efficacy. High potency, 
however, will only be beneficial in tumor therapy if it is specific for 
the target cell, in the sense that the effector function remains 
inactive outside the cell and becomes activated only after binding to 
and entering the target cell. Over the last few years such molecules, 
named immunotoxins (ITS), have been constructed by conjugating toxins 
from bacteria or plants to MoAbs. Many investigators have contributed 
insights into the mechanisms by which these toxins kill cells [41,42]. 
The toxins most widely utilized are diphteria toxin, the exotoxin 
secreted by Corynebacterium diphteria, and the plant toxin ricin from 
the seeds of Ricinus communis. Besides, abrin, gelonin pokeweed 
antiviral protein (PAP), saporin or Pseudomonas exotoxin are used as 
toxic subunit of the IT. Toxins, such as ricin, consist of two chains: 
the toxic Α-chain and the binding sites containing B-chain. The B-chain 
is a galactose-specific lectin which binds to virtually all eukaryotic 
cells followed by endocytotosis. This facilitates the penetration of 
the Α-chain into the cytoplasm [43]. The Α-chain is a N-glycosidase 
that cleaves the N-glycosidic bond of a particular adenoside residue 
from ribosomal RNA and inhibits strongly and irreversibly the protein 
synthesis of the target cell [44]. No more than 1800 ricin molecules 
bound to the cell surface seem to be required for the penetration into 
the cytoplasm of at least one Α-chain which is sufficient to kill the 
cell [45]. Immunotoxins prepared with intact toxins are extremely potent 
cytotoxic agents in vitro for cells carrying the appropriate target 
antigen, often matching or even surpassing the toxicity of the native 
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toxin [46]. However, though the nonspecific binding by the B-chain can 
be blocked in vitro by high concentrations of sugars such as galactose 
and lactose [47,48], these sugars are rapidly excreted in vivo [49] and 
the release of whole ricin from conjugates after infusion of treated 
marrow may be hazardous to the patient [50]. High concentrations of 
galactose or lactose are toxic for animals so that blocking of binding 
sites does not appear to be feasible in human beings. Therefore, the 
galactose binding sites have to be blocked by other agents than sugars 
[49] or the Α-chain has to be separated from the B-chain and coupled to 
a MoAb, which replaces the function of the B-chain by enhancing the 
internalization of the Α-chain. The low toxicity of ricin A-chain 
conjugates in vivo (LD50 in mice: 22.3 mg/kg) compares favourably to 
intact ricin conjugates (LD50 in mice: 0.016 mg/kg) [51]. 
The ricin A-chain ITs kill more slowly than ITs with intact ricin, 
which makes it desirable to develop methods to increase their potency. 
Electron microscopic investigations suggested that the IT might be 
destroyed in the secundary lysosomes [52,53]. Therefore the influence of 
lysosomotrophic agents was studied. These investigations showed that 
ammonium chloride and carboxylic ionophores have a highly potentiating 
effect on the cytotoxicity of ricin A-chain ITs. This resulted in an 
efficacy even exceeding that of intact ricin [54]. Moreover, the choice 
of the MoAb will influence the cytotoxic potential of the IT [63,64]. 
3. PRODUCTION OF НІСШ A-CHAIN РИШЖЯШДге 
The A-chain (Mw 30,000) and the B-chain (Mw 33,000) of ricin (Mw 63,000) 
can be dissociated by reduction of the disulfide bridge between the two 
ricin chains with ß-mercaptoethanol [55]. The A-chain can be purified 
by chromatography on DEAE-cellulose. Contaminating B-chains can be 
removed by lectin affinity chromatography or by antibody affinity 
chromatography (Sepharose-coupled antibody to the B-chain in the 
presence of lactose) [55]. If ricin is dissociated in the two subunits 
it shows 100-times higher cytotoxicity in a cell free system of isolated 
ribosomes as compared to the intact form, suggesting that in the intact 
ricin molecule the A-chain is sterically hindered by the B-chain [56]. 
14 
The intersubunit disulfide bridge appears to be essential for the 
cytotoxicity of the ricin and plays a role in the transmembrane 
transport of the ricin A-chain [57], implicating that the ricin A-chain 
has to be conjugated to a MoAb by a disulfide linkage. The importance of 
the nature of the linkage was supported by the finding that a more 
stable thioether cross-link decreased the cytotoxicity of the IT 
[48,58]. However, by the lack of a free sulfide group in the MoAb an 
artificial disulfide bridge has to be created by a heterobifunctional 
cross-linker. N-succinimidyl 3-(2 pyridyldithiol propionate (SPDP) is 
commonly used for this purpose [59]. The preparation of ITS with SPDP is 
described in figure 1. 
a. MoAb-NH2 + 
0 > 
II / 
u ArS-S-CH2-CH2-C-0-N 
"Ν V 
О 
V/ 
0 
S-S-CH2-CH2-C-0-NH-MoAb + HN 
ь 
>/ 
b. MoAb-NH-0-C-CH2-CH2-S-S 
N-
*• HS-RICIN A > 
MoAb-NH-0-C-CH2-CH2-S-S-RICIN A + S; 
/ 
Fig. 1. Synthesis of an immunotoxin. 
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Fab- or FfabMz-fragments of the antibody are to be preferred to 
intact antibodies to circumvent the nonspecific binding of the Fc-
receptor. The cytotoxicity of Fab-fragment containing ITS is 
significantly less than FtabMz-lTs or ITs of intact MoAbs [58,60]. The 
Fc-receptor binding does not substantially influence the specificity of 
the ITs in in vitro bone marrow purging, whereas after bone marrow 
infusion the concentration of the contaminating IT will be very low and 
the ITs are eliminated rapidly from the bloodstream [61]. 
In conclusion, the use of ITs composed of an intact MoAb and ricin 
Α-chain, coupled with SPDP, appears to be an effective approach for the 
elimination of normal and malignant Τ cells in bone marrow. Though the 
before mentioned approaches will not be the ultimate solution for the 
treatment of leuXemia, it will be a step forward on the road to a 
successful bone marrow transplantation. Moreover it opens the 
possibility for in vivo application to reduce the residual malignant 
cells after intensive radiochemotherapy. 
4. M M OF THE INVESTIGATIOHS 
In this thesis the use of ITs for the ex vivo elimination of malignant Τ 
cells in autologous bone marrow grafts and normal Τ cells in allogeneic 
bone marrow grafts was studied. The ITs were composed of monoclonal 
antibodies directed against τ cell antigens conjugated to ricin A-chain. 
Various parameters influencing the efficacy of ricin A ITs were 
analyzed. The suitability of different Τ cell antigens as target for ITs 
in relation to the quantitative expression of the antigens and their 
ability to internalize ITs was studied (Chapter 2). 
The susceptibility of resting and activated normal human Τ cells to 
ITs in comparison with malignant Τ cell lines was studied. The effect of 
lysosomotropic agents on the cytotoxicity of the ITs was investigated 
(Chapter 3). 
The efficacy of ITs to normal τ cell subpopulations was compared 
with complement mediated cytotoxicity. The effect of the different anti-
T cell ITs and MoAbs with complement on the natural killer cell activity 
was studied (Chapter 4). 
The susceptibility of human malignant Τ cells to ITs was determined 
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as well as the optimal conditions for the ex vivo incubation of 
autologous bone marrow prior to reinfusion (Chapter 5). 
The application of anti-T cell ITs for the purging of bone marrow in 
autologous ΒΜΓ as treatment for acute Τ cell leukemia and lymphoma was 
analyzed in a clinical trial (Chapter 6). 
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ABSTRACT 
Inmunotoxins (IT) appear to vary considerably in their killing 
efficiency towards antigen positive cells. In order to unravel the 
mechanisms underlying these differences, the parameters responsible for 
these variations were studied. The efficacy of the monoclonal antibodies 
(MoAb) WT32 (CD3), 0KT4 (CD4), T101 (CDS), WT1 (CD7), and WT82 (CD8) 
conjugated to ricin Α-chain was expressed by the extent of protein 
synthesis inhibition of four leakaemic Τ cell lines (СЕМ, GHl, Jurkat, 
and HPB-ALL). Large differences in cytotoxicity were observed. Efficient 
inhibition of protein synthesis was seen with anti-CD3 IT, anti-CD5 IT, 
and anti-CD7 IT. in these cases the cytotoxicity was related to the 
antigen desity on the target cell membrane. Anti-CD4 IT inhibited poorly 
and anti-CD8 IT was ineffective, even on cell lines with a high 
expression of the corresponding antigen. When antigen density and 
cytotoxicity were plotted for all CD-antigens, no correlation could be 
found. Subsequently, internalization was studied with 12Slodine-labelled 
antibodies. Anti-CD7 showed the fastest internalization rate, followed 
by anti-CD3 and anti-CD5. Anti-CD4 and anti-CD8 antibodies were 
respecively moderately and hardly internalized. When the absolute amount 
of internalized MoAb was calculated, a highly significant correlation 
with cytotoxicity was found. We conclude that the degree of antigen 
expression is not so important as the absolute amount of antibody 
internalized in predicting the efficacy of IT. 
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штаовдстіси 
Immunotoxins (IT) exert a highly specific cytotoxicity to target cells 
by combining the specificity of an antibody and the cytotoxic properties 
of a toxin. The Α-chain of the phytolectin ricin is an extremely potent 
irreversible inhibitor of protein synthesis by catalytical inactivation 
of the 60S ribosomal subunit (Endo & Tsurugi, 1987). The Α-chain is only 
effective after translocation into the cytoplasm of the cell (Olsnes & 
Pihl, 1973), following an initial binding of the IT to the antigen and 
receptor-mediated endocytosis (Carrière et al, 1985). Ricin Α-chain IT 
have slower kinetics than IT containing intact ricin (Vallera et al, 
1984; Youle b Neville, 1982), possibly due to the capacity of the B-
chain to increase the uptake of Α-chain in the cytoplasm by facilitating 
the translocation of the Α-chain from the endosóme into the cytosol 
(Mcintosh et al, 1983; Vitetta, 1986). However, the B-chain containing 
conjugates possess a lower specific cytotoxicity and therefore are less 
suitable for specific elimination of malignant cells (Skilleter et al, 
1981). The potency of Α-chain IT can be increased considerably by 
ammonium chloride (Casellas et al, 1984). 
IT seem to be useful tools for the ex vivo elimination of leukaemic 
cells or mature Τ cells from bone marrow (Myers et al, 1984; Casellas et 
al, 1985; Derocq et al, 1987; Preijers et al, 1988a). Before clinical 
application of IT the conditions for optimal and selective elimination 
of malignant cells should be determined. Effective IT should satisfy the 
following conditions: high density of the target antigen (Myers et al, 
1984; Laurent et al, 1986), intracellular stability of the A-chain 
enabling inhibition of protein synthesis (Olsnes & Pihl, 1983), and high 
internalization capacity of the target antigen. 
In this paper we report that, although the desity of the target 
antigen on the cell membrane is a prerequisite for effectiveness of IT, 
the absolute amount of antibody internalized shows the best correlation 
with cytotoxicity of the different IT directed against T-cell differen­
tiation antigens. 
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MATERIALS AND METHODS 
Ceil lines 
The used human T-ALL cell lines (СЕМ, GH1, Jurkat, and HPB-ALL) were 
cultured in RPMI 1640 (Flow Labs, Irvine, Scotland), supplemented with 
5% heat inactivated fetal calf serum (Flow Labs), 2 mM glutamine, 1 mM 
sodium pyruvate, and gentamycine (50 ug/ml) at 370C in a humidified 
atmosphere with 5% C02 in air. 
Monoclonal antibodies 
Murine anti-human Τ cell MoAb: WT1, anti-CD7 (Tax et al, 1984b); WT32, 
anti-CD3 (Tax et al, 1983); WT82, anti-CD8 (Tax et al, 1984a); T101, 
anti-CD5 (Royston et al, 1980); and OKT4, anti-CD4 (Rung et al, 1979) 
were purified using Staphylococcus aureus protein A coupled to Sepharose 
(Pharmacia Ltd, Uppsala, Sweden). 
Imminotoxins 
Ricin Α-chain was kindly provided by Dr F.K.Jansen (Centre de Recherches 
Clin Midy-Group Sanofi, Montpellier, France). MoAb were coupled to ricin 
A by N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP, Pharmacia) as 
described previously (Preijers et al, 1988a). Final products were 
assayed by sodium dodecyl sulphate (SDS) gel electropheresis to 
determine the molecular weight. The molar ratio of Α-chain and antibody 
were determined by radioimmunoassay and appeared to vary between 1 and 
1.8. By flow cytometry (FCM) and enzyme-linked immunosorbent assay 
(ELISA; Tax et al, 1984b) it was demonstrated that the antibody binding 
activity was preserved after conjugation. The nonspecific cytotoxicity 
of all conjugates was tested on cell lines which did not express the 
relevant antigen. TlOl-ricin A was kindly donated by Dr P. Casellas 
(Centre de Recherches Clin Midy). 
Cytotoxicity of IT to cell lines 
Cytotoxicity assays were carried out in 96-weli U-bottom plates (Costar, 
Cambridge, Massachusetts) in triplicate. Each well containing 105 cells 
in culture medium was supplemented with varying concentrations of ricin 
Α-chain conjugates with or without 6 mM ГШ
Л
С1 in a final volume of 200 
μΐ. The cells were incubated for 24 hrs at 3 7 ^ in a humidified 
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incubator with 5% C02 in air, followed by a labelling for 24 hrs with 
0.5 цСі 3H-leucine (TRK510, Amersham International pic, England). Cells 
were harvested and radioactivity was counted. The incorporation of 3H-
leucine in the presence of 1 mM cycloheximide was used as background 
value. The cytotoxicity was expressed as percentage inhibition of 3H-
leucine incorporation of untreated cells corrected for the background. 
Antigen density on the cell membrane 
The expression of antigen was determined by MoAb labelled with 125lodine 
(Amersham, Buckinghamshire, England) using the chloramine Τ method 
(Hunter, 1973). The concentration and specific activity of the labelled 
MoAb were determined by radioimmunoassay and binding assay with limiting 
quantities of labelled antibody. Binding assays to determine the 
saturation level of MoAb were carried out at 40C to avoid 
internalization of the bound MoAb. The maximal number of binding sites 
per cell was calculated after incubation of 106 cells for 1 hr. 
Determination of internalization of antibodies 
The internalization of antibodies was determined as decribed previously 
(Tax et al, 1987). Briefly, target cells were incubated with i**i-
MoAb for various times at respectively 370C or 40C and radioactivity was 
counted. The amount of internalized MoAb was determined after removing 
the cell bound MoAb by incubation with either pronase (WT1 and WT82) or 
buffer at pH2 (WT32, OKT4 and T101). The percentage internalized 
antibody (%I) was calculated by the equation: 
%I = ( A370 - A4'' ) χ 100 
TA" 
T4 0 represents radioactivity after the first incubation at 40C, and A37 0 
and Α4° the radioactivity of the samples after stripping the antibodies 
from the cell membrane, all corrected for nonspecific binding (always 
<250 cpm, < n of the total bound label). 
29 
Table 1. Dose dependent cytotoxicity of IT to T-ALL cell lines 
and potentiating effect of NH^CL. 
IT 
WT32-ricin A 
+m*cL 
0КТ4-ГІСІП A 
+Ш
Л
С1 
T l O l - r i c i n A 
+Ш
Л
С1 
WTl-r ic in A 
+Ш
Д
С1 
WT82-ricin A 
+Ш
Л
С1 
СЕМ 
> 1 0 - н 
> 1 0 - β 
З х Ю -
4 
7 Х І 0 - 1 0 
2 Х І 0 - 1 0 
Ю -
1 1 
З х Ю -
1 1 
8 х 1 0 - 1 2 
> 1 0 - а 
> 1 0 - в 
ID50- (М) 
GH1 
> 1 0 - в 
> 1 0 - в 
4 x 1 0 - ' 
7 Х І 0 - 1 1 
Ю -
1 0 
Ю -
1 2 
З х Ю -
1 2 
З х Ю -
1 3 
> 1 0 - в 
> 1 0 - 8 
Jurkat 
S x l O - 1 0 
гхіо-
1 0 
Ю -
9 
1 0 - 1 0 
8 Х І 0 - 1 1 
2 Х І 0 - 1 1 
2 х 1 0 - 1 1 
З х Ю -
1 2 
> 1 0 - в 
5ХІ0- 9 
HPB-ALL 
З х Ю -
1 1 
2 Х І 0 - 1 1 
2x10-* 
2 х 1 0 - 1 0 
З х Ю -
1 1 
1 . 5 Х І 0 - 1 1 
7 х Ю - 9 
Ю -
9 
>ю-н 
10-« 
Cells were incubated with a range of IT concentrations with or 
without 6 mM airaronium chloride for 24 hrs followed by 3H-leucine 
uptake for another 24 hrs. Data represent the mean of triplicate 
incubations of minimally five experiments. 
'Concentration of IT which inhibited 50% of 3H-leucine incorpor­
ation compared to untreated controls. 
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RESULTS 
Cytotoxicity of anti-T cell IT on different cell lines 
The cell lines СЕМ, GHl, Jurkat, and HPB-ALL were incubated with IT 
varying from 10-e to ΙΟ-12 M with or without 6 mM ammonium chloride. The 
results, expressed as concentrations of IT inhibiting 50% of the protein 
synthesis (ID50), are given in Table 1. The level of protein synthesis 
10 10 10 •" 10 " 10 
CONCENTRATION I T (M) 
Fig. 1. Cytotoxicity of IT on Jurkat. Jurkat cells in culture medium 
were treated for 24 hr with different IT followed by 24 hr 
uptake of 3H-leucine. Inhibition of protein synthesis is 
expressed as percentage 3H-leucine incorporation of untreated 
controls. Each point represents the mean of triplicate 
incubation from minimally five experiments. Standard deviations 
were less than 10%. 
(•) WT32-ricin A; (·) 0KT4-ricin A; (A) TlOl-ricin A; 
(O) WTl-ricinA; (Δ) WT82-ricin A; (*) free ricin A. 
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in untreated cells was similar for the different cell lines: GH1 (24285 
+ 6532 cpm), HPB-ALL (23288 + 5730 cpm) , JurJcat (21729 + 4531 cpm) and 
СЕМ (21665 + 5023 cpm) (n=20). Ammonium chloride (6 mM) as such did not 
affect protein synthesis. Concentrations higher than 6 mM substantially 
influenced the protein synthesis. 
Results of representative experiments with the cell line Jurkat 
expressing antigens for all the used IT, are depicted in Fig. 1. In this 
case WT82-ricin A did not induce a significant reduction of protein 
synthesis. The strongest decrease of 3H-leucine uptake was found with 
WTl-ricin A, which was 50-fold more effective than OKT-ricin A. 
Native ricin Α-chain (10-e M) gave only 6% reduction of protein 
synthesis in the absence and 11% reduction in the presence of 6 mM 
ammonium chloride for Jurkat. These values were the same or even lower 
for the other cell lines used (data not shown). 
Toxicity of IT in relation to antigen density 
The tested cell lines varied greatly in antigen density (Table 2). СЕМ 
showed no detectable expression of CD3 and CD8. The number of bound MoAb 
was compared with the extent of cytotoxicity of the IT of the different 
Table 2. Antigen density of Τ cell lines. 
Antigen density (average no. of molecules 
bound per cell χ IO-3 + SD) 
CD 
CD3 
CD4 
CD5 
CD7 
CD8 
(MoAB) 
(WT32) 
(OKT4) 
(T101) 
(WT1) 
(WT82) 
СЕМ 
0+0 
11+1 
25+1 
63+3 
0+0 
GH1 
6+2 
4+0 
32+0 
175+25 
16+2 
Jurkat 
73+9 
65+10 
52+6 
106+5 
141+8 
HPB-ALL 
185+12 
43+1 
64+3 
20+1 
75+0 
SD = standard deviation. Antigen density is measured by binding 
analysis of l"i-MoAb at 40C. Data represent the mean of three 
independent measurements. 
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Fig. 2. Efficacy of IT in relation to antigen density of CD7 (A), CD3 
(B), CD5 (C), CD4 (D), and CD8 (D) on the T-cell lines СЕМ (·), 
GH1 (О), Jurkat ( • ), and HPB-ALL ( • ). Results are expressed 
as dose ID50 in relation to the maximal binding per cell of the 
concerning MoAb. Each ID50 value is the mean of triplicates of 
at least five independent experiments and has a standard 
deviation of less than 10%. MoAb binding was measured by i 2 5 i -
labelled MoAb in three independent experiments, standard lines 
were obtained from linear regression analysis. Only ID50 values 
lower than 10-e M ricin A IT were used for linear regression 
analysis. 
MoAb (Fig. 2). Comparison of the ID50 of WTl-ncin A with the capacity 
of the cell lines to bind WT1, as shown in Fig 2A, showed a strong 
correlation (p<0.0l) suggesting that the cytotoxic efficacy of this IT 
depends on the amount of antigen bound IT. Analysis of data of CD4 and 
CDS antigens gave a significant correlation with respectively p<0.05 and 
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p<0.01 (Figs. 2C and 2D). The number of IDSO's of WT32-ricin A (CD3; 
Fig. 2B) below 10-β M were too small for linear regression evaluation, 
caused by a moderate or no expression of CD3 by respectively GHl and 
СЕМ. Therefore a correlation could not reliably be calculated, but again 
the cell line with the highest density was most sensitive to WT32-ricin 
A. All ID50 values of WT82-ricin A (CD8) Were higher than Ю- 8 M, even 
for cell lines with high antigen expression, indicating a very low 
efficacy of this IT. 
When all data were pooled irrespective of CD antigen involved, no 
significant relationship was found between antigen density and ID50. 
This can also be derived from the variation in slope of the different 
linear regression lines in Fig 2. These results indicate that the 
antigen density is not the only factor that determines the cytotoxic 
efficacy of IT. 
® 
SURFACE BOUND 
INTERNALIZED 
(D 
INTERNALIZED 
/ 
SURFACE 
120 
TIME (KIN.) 
Fig. 3. Internalization of anti-CD7 MoAb (WT1). ^^I-labelled WTl was 
incubated with СЕМ at 40C (A) and 37°C (B) for various periods 
of time as indicated on the abscissa. Cell-associated 125I-MoAb 
was counted. Internalized MoAb was determined after treating the 
cells with pronase as described in Materials and Methods. 
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Internalization of monoclonal antibodies 
Because IT exert their function in the cytoplasm, we studied the 
capacity of the various antigens to internalize surface bound antibodies 
and ricin Α-chain conjugated antibodies. The amount of antibody which 
was internalized within 1 hr after binding the specific antigen was 
examined with lzsI-labelled antibodies. An example of the binding and 
internalization kinetics is depicted in Fig. 3, showing an incubation of 
СЕМ cells with anti-CD7 (WTl). similar internalization pattern was 
observed with "^I-WTl-ricin A. The amount of surface bound antibodies 
at 40C and 370C is comparable. However, at 37°C the total amount of 
antibody has increased due to the internalization of antibody which only 
occurs to a significant degree at 370C. The percentage internalized 
antibody after an incubation of l hr at 370C was calculated for the used 
IT (Table 3). The highest percentage of internalized antibody was found 
for WTl, followed by WT32, and T101. The extent of internalization was 
Table 3. Internalization of 1::*sl-labelled MoAb by Τ cell lines. 
Internalized 12=І-1аЬе11еа MoAb (% + SD) 
CD (MoAB) СЕМ GH1 Jurkat HPB-ALL 
CD3 
CD4 
CD5 
CD7 
CD8 
(WT32) 
(OKT4) 
(T101) 
(WTl) 
(WT82) 
—* 
10+4 
34+3 
76+10 
_* 
30+2 
12+7 
38+6 
90+3 
5+1 
69+5 
19+5 
38+1 
72+2 
8+2 
SD = standard deviation. Cells were treated with 1Z5i-MoAb for l 
hr at 37° С and 4° С Radioactivity was counted and sur­
face bound MoAb was removed as described in Materials and 
Methods. Percentage of internalized 12"iI-MoAb was calculated 
from totally bound 125I-MoAb. Data represent the mean of 
triplicate incubations for each test. 
*No detectable expression of the antigen. 
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Fig. 4. Cytotoxicity of ricin Α-chain IT in relation with the amount of 
internalized MoAb. Results are expressed as ID50 of ricin A-
chain IT directed against CD3 ( • ), CD4 ( · ), CD5 ( • ), CD7 
(O), and CD8 ( Δ ) in the absence (A) or the presence (B) of 6 
mM Ш
Л
СЬ plotted against the total number of internalized MoAb, 
determined for the leukaemic Τ cell lines: СЕМ, GH1, Jurkat, and 
HPB-ALL. The standard line was obtained from linear regression 
analysis. Each single point represents the individual values of 
the ID50 and the total number of internalized MoAb of the 
described cell lines. 
moderate for 0KT4 and very low for WT82. Ammonium chloride did not 
influence the internalization (data not shown). Internalization patterns 
of IT were comparable with those of the corresponding free antibody 
showing that the conjugation procedure did not influence the 
internalization characteristics of the antibody. 
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Cytotoxic efficacy of IT in relation with the amount of internalized 
MoAb 
From the data of Tables 2 and 3 the absolute amounts of internalized 
antibodies after an incubation of 1 hr under antigen saturating 
conditions were calculated. These values were compared with the ID50 
values of the IT involved. A highly significant correlation (r=0.78 
with p<0.001) was found (Fig. 4A). The number of internalized anti-CD8 
and anti-CD4 antibodies was very low even for cell lines with high 
antigen density. This contrasted with the intracellular amount of MoAb 
which were well internalized, such as anti-CD3, anti-CD5, and anti-CD7. 
These results show that only after combining the antigen density and the 
internalization characteristics of this antigen, thus giving absolute 
figures for the amount of internalized IT, a relation with its ID50 
becomes apparent. Incubation with ITs in the presence of 6 mM ammonium 
chloride decreased the ID50 about 5-fold without changing the 
correlation (p<0.01) between cytotoxicity and the number of 
internalized antibodies (Fig. 4B). The slope of the linear regression 
line remained unchanged. 
DISCUSSION 
Previous studies with WTl-ricin A (anti-CD7; Myers et al, 1984) and 
TlOl-ricin A (anti-CD5; Laurent et al, 1986) have suggested a direct 
relation between antigen density and cytotoxicity of IT for τ cell 
lines. Comparable data with WTl were also found for fresh leuJcaemic T 
cells (Preijers et al, 1988b). However, it is questionable whether this 
relation exists for all IT. In this report we showed that the 
cytotoxicity depends on the amount of internalized IT rather than on 
antigen density. Internalization of IT was determined after removing the 
cell surface bound MoAb from the target cell, whereas the number of 
binding sites on the cell surface was determined with saturating 
concentrations of lzsI-MoAb and with FCM (data not shown). The latter 
data appeared to be in accordance with observations of Poncelet t, 
Carayon (1985). 
We studied the relation between cytotoxicity, antigen density, and 
internalization of five ricin Α-chain IT to leukaemic Τ cell lines. Our 
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results are in agreement with the data of Myers et al (1984) and Laurent 
et al (1986) concerning the relation between antigen density and 
cytotoxicity, but this relation only maintains for IT which were 
internalized in a high amount. For instance the Τ cell lines Jurkat and 
HPB-ALL with a high density of CD8, internalized a very low amount of 
WT82 which is in agreement with data of Meuer et al (1982). This 
indicates that anti-CD8 do not induce a decrease of the concerning cell 
surface antigen (modulation). The ID50 of WT82-ricin A was higher than 
10-β M which confirms the findings of Derocq et al (1987) and Till et al 
(1988). 
CD4 antigen was also slightly internalized and comparable data were 
obtained from modulation experiments with anti-leu3a (Rinnooy Kan et al, 
1983). We showed that 0KT4-ricin A was poorly cytotoxic according the 
results of Derocq et al (1987). 
The antigen with fastest internalization rate was CD7, followed by 
CD3 and CD5. We found that the relative degree of internalization of the 
CD7 antigen for all target cells studied was more than twice that of the 
the CD5 antigen (Table 3). In contrast, Leonard et al (1985) suggested, 
based on inhibition studied, that 3Al-ricin (anti-CD7) was less well 
internalized and therefore less effective than TlOl-ricin. Similar 
results were obtained by Stong et al (1985) using G3.7-ricin (anti-CD7) 
and TlOl-ricin, despite equivalent target cell binding. Obviously, 
besides the internalization rate, the intracellular handling of an IT is 
of importance for its cytotoxic effect. 
The internalization of WT32 in l hr varied between 30% for GHl and 
69% for Jurkat comparable with findings of Tax et al (1987). Krangel 
(1987) demonstrated that the CD3-complex was partly internalized and 
recycled during a 3 hr period of examination, allowing a continuous 
internalization of IT. Rinnooy Kan et al (1983) showed complete 
modulation of CD3, but after a much longer incubation period in which 
degradation may occur. 
Cytotoxicity of IT could be strongly enhanced by ammonium chloride. 
Ammonium chloride had no influence on the amount of internalized IT 
itself. The fact that lower amounts of IT were necessary for 50% protein 
synthesis inhibition (ID50: Fig. 4B) indicates that ammonium chloride 
most likely facilitates the transport of IT to the ribosomes by 
modifying the traffic between the different intracellular compartments 
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(Carrière et al, 1985). The average reduction of the ID50 was a factor 5, 
but differed considerably per antigen and per cell line. These results 
are also evidence for a different intracellular handling of ricin A per 
cell type. We conclude that, besides antigen density and an effective 
intracellular transport of ricin A to the site of action, the 
internalization of IT is the most important factor for a high efficacy. 
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ABSTRACT 
In the context of ex vivo Τ cell elimination from bone marrow, the 
anti-T cell cytotoxic potential of immunotoxins (IT) prepared by 
conjugation of the monoclonal antibodies (MoAb) WT32 (CD3), T101 (CD5), 
and WTl (CD7) to ricin Α-chain was evaluated. The cytotoxicity of IT 
was based on protein synthesis inhibition in the human Τ cell lines: 
GH1, СЕМ, HPB-ALL, and Jurkat, and appeared closely related to the 
antigen density and internalization rate of the IT. Normal unstimulated 
Τ cells appeared to be rather insensitive to IT not due to a low antigen 
density or decreased internalization. The cytotoxicity of IT to τ cells 
could be enhanced considerably by NH4Cl. Treatment of Τ cells with a 
cocktail of IT (l0-e M) and 20 mM NH4Cl resulted in a 5000-fold 
cytoreduction as measured by clonogenic assays of limiting τ cell 
dilutions, whereas the haematopoietic progenitor cells remained 
unaltered. Stimulation of Τ cells with phytohaemagglutinin (PHA) prior 
to incubation with IT, considerably increased the sensitivity to IT 
treatment. Thus, normal Τ cells are less sensitive to anti-T cell IT 
than Τ cell lines and activated Τ cells. This suggests that a low 
protein synthesis is responsible for the resistance to IT. However, a 
high specific cytotoxicity of IT to normal Τ cells can be achieved in 
the presence of 20 mM ammonium chloride. 
дпдшостюи 
In vitro elimination of subpopulations from bone marrow has been 
attempted with monoclonal antibodies (MoAb). To increase the specific 
cytotoxicity MoAb have been conjugated to toxins such as the phytolectin 
ricin. These conjugates, immunotoxins (IT), appeared to be effective 
for the ex vivo elimination of malignant Τ cells from bone marrow 
[4,12,15,16,26,33]. The specificity of ricin IT has been improved by 
conjugation to the ricin Α-chain after the removal of the ricin B-chain 
[18]. Although ricin Α-chain IT are less potent than conjugates with 
intact ricin [31,35,38], their cytotoxicity can be increased 
considerably by lysosomotropic amines or carboxylic ionophores [3]. The 
cytotoxic potential of IT has been based mostly on the inhibition of 
protein synthesis or colony formation of cell lines. The magnitude of 
cytoreduction obtained by IT in cell lines varies from 1 log to more 
than 6 logs, and appears to be related to antigen density and antigen 
internalization capacity [20a], the actual intracellular toxin concen­
tration at the site of action, the nature of the toxin, and the cell 
line being studied [4,12,15,16,21,26,33]. 
IT are also applied to remove immunocompetent Τ cells from donor 
bone marrow to prevent acute graft-versus-host disease (GVHD) after 
allogeneic bone marrow transplantation (BMT) [6,7]. Exposure of bone 
marrow cells to ricin Α-chain IT in the presence of ammonium chloride 
considerably potentiates the elimination of Τ cells [11,14,24]. At 
present, only a few experimental data are available on the efficacy of 
ricin Α-chain IT to normal Τ cells in comparison to cell lines in the 
absence of ammonium chloride [25,35]. 
This paper reports the cytotoxic effects of different ricin A-
chain IT directed against CD3, CD5, and CD7 on normal τ cells and τ cell 
lines in relation to their antigen density and internalization capacity. 
The specific cytotoxic efficacy of IT was enhanced considerably by 
ammonium chloride. The cytotoxic effect of IT on haematopoietic 
progenitor cells remained negligible. 
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MATERIALS AND METOODS 
Isolation of Τ lymphocytes and culturing of cell lines 
Blood mononuclear cells were isolated from buffy coats by density 
centrifugation on 1.077 g/ml Ficoll-Hypaque (Pharmacia Ltd, Uppsala, 
Sweden) and resuspended in RPMI 1640 (Dutch modification; Flow Labs, 
Irvine, UK). Τ cells were enriched by removal of adherent cells by 
nylon wool filtration [20]. This cell population consisted of 90 + 4% 
CD2/CD3 positive cells, as determined by flow cytometry (FCM). The cell 
suspension was supplemented with 10% heat inactivated fetal calf serum 
(FCS) (HyClone Labs, Logan, Utah), 2 mM glutamine, 1 mM sodium pyruvate 
and gentamycin (50 \ig/ml). 
In some experiments 2xl06 Τ cells/ml were stimulated with 50 ug/ml 
phytohaemagglutinin (PHA; Welcome Diagnostics, Dartford, UK) for 3 days 
at 37°C in a humidified atmosphere with 5% C02 in air. 
Human T-ALL cell lines (GHl, СЕМ, HPB-ALL, and Jurkat) were cultured 
in RPMI 1640 containing 5% FCS. 
Monoclonal antibodies and preparation of immunotoxins 
Murine anti-human Τ cell MoAb: WT1, anti-CD7 [30,36]; WT32, anti-CD3 
[29]; and T101, anti-CD5 [23] were purified by means of Staphylococcus 
aureus protein A coupled to Sepharose (Pharmacia). 
MoAb were treated with a 10-fold excess of succinimidyl 3-(2-
pyridyldithio)propionate (SPDP; Pharmacia) [i]. The modified antibodies 
were incubated overnight with a 2.5-fold molar excess of ricin A-chain 
(kindly provided by Dr F.К. Jansen, Centre de Recherches Clin Midy, 
Montpellier, France) at 30oC. Free antibody and free A-chain were 
removed by Sephacryl S200 gel filtration. Conjugates were analysed by 
SDS-PAGE. The molar ratio of ricin A-chain and antibody, determined by 
radioimmunossay, appeared to vary between l and 1.8. The preservation 
of the antibody-binding activity after conjugation was proven by FCM and 
enzyme-linked immunosorbent assay (ELISA) [30]. TlOl-ricin A was kindly 
donated by Dr P. Casellas (Centre de Recherches Clin Midy). 
Antigen density on the cell menbrane 
The maximum number of binding sites was determined by MoAb labelled with 
125lodine (Amersham International, Amersham, Bucks, UK) using the 
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chloramine Τ method [9]. The concentration and specific activity of the 
125I-labelled MoAb were determined by radioimmunoassay and binding 
assay, respectively, with limiting quantities of labelled antibody. 
Binding assays to determine the saturating level of MoAb were performed 
at 40C to avoid internalization of the bound MoAb. The maximum number of 
binding sites per cell was calculated after incubation for one hour. 
Internalization of MoAb 
The internalization of MoAb was determined as described previously [28]. 
The percentage internalized antibody (%l) was calculated by the 
equation: 
%I = ( A37° - A4'' ) χ 100. 
T4° 
T4 0 represents total bound radioactivity after incubation at 4"C, and 
A37° and A4 0 the radioactivity of the samples after stripping the MoAb 
from the cell membrane, all corrected for background values. 
Cytotoxicity of IT to cell lines 
Cytotoxicity assays were carried out in triplicate in 96-well U-bottomed 
plates (Costar, Cambridge, Mass, USA). Each well was filled with ΙΟ"5 
cells in culture medium, supplemented with varying concentrations of 
IT to a final volume of 200 ці. Cells were incubated for 24 hrs 
followed by labelling for 24 hrs with 0.5 \iCi ""H-leucine (TRK510, 
Amersham). The cells were harvested and radioactivity was counted. The 
background incorporation was determined in the presence of 1 mM 
cycloheximide. The cytotoxicity was expressed as percentage inhibition 
of 3H-leucine incorporation of untreated cells corrected for the 
background value. 
Protein synthesis inhibition of normal Τ cells 
Τ cells (10E cells/ml) were incubated with IT m the absence or 
presence of 20 mM NH^Cl for 24 hrs, subsequently cultured in triplicate 
at a concentration of 10 5 cells per well with or without 50 цд/ті PHA 
for 48 hrs. Cells were labelled with 3H-leucine, harvested and counted 
as described. The cytotoxicity was expressed as percentage inhibition of 
the 3H-leucine incorporation of PHA-stimulated cells not treated with 
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IT and corrected for the background incorporation of unstimulated cells. 
Cytotoxicity of iTs to PHA-stimulated τ cells was determined as 
described for T cell lines. Unstimulated cells were cultured under the 
same conditions to determine the background incorporation. 
Limiting dilution assay for τ cells 
Τ cells were isolated from fresh blood, incubated with ricin Α-chain IT 
in the absence or presence of 20 mM ammonium chloride, washed, and 
suspended in RPMI 1640 supplemented with 15% FCS, 20% interleukin-2 (IL-
2; Lymphocult, Biotest, Fairfield, N.J., USA), 15% PHA-leukocyte-
conditioned medium (PHA-LCM) , 50 цд/ті PHA, and 10 ng/ml phorbol 12-
myristate 13-acetate (TPA). Untreated cells were diluted to 5, 10, 25, 
and 50 cells per well, treated cells to 50, 500, and 5000 cells per 
well in 96-well round-bottomed microtitre plates (200 μΐ per well). 
After 14 days of culture the proliferative lymphocytes in each well were 
counted. Cloning efficiency was determined by the minimum chi-square 
method from the Poisson distribution between cell number seeded per well 
and the logarithm of the percentage of negative wells [27]. 
Cytotoxicity of IT to bone marrow progenitor cells 
Bone marrow was obtained after informed consent from patients 
undergoing cardiac surgery. Erythrocytes and mature granulocytes were 
removed by gradient centri fugation on Ficoll (1.077 g/ml). Cells 
(10B/ml) were incubated with IT (10-a M) with or without 20 mM ammonium 
chloride for 24 hrs. Cells were washed and the reduction of bone marrow 
progenitors was determined in clonogenic assays of granulocyte/ 
macrophage colony-forming cells (CFU-GM) and erythroid burst-forming 
cells (BFU-E) as described previously [37]. 
RESULTS 
Cytotoxicity of IT to Τ cells 
Cytotoxicity of the anti-T cell IT WT32-ricin A, TlOl-ricin A, and WT1-
ricin A was evaluated on Τ cells. Protein synthesis, determined 
immediately after incubation with a cocktail of these IT representing 
10-' M ricin A, was slightly reduced (less than 20%). Incubation with 
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СОНСЕИТВЛТЮК or ІШМ ИОТОЖІЯ (Mi 
Fi4· 1- Cytotoxicity of IT to normal τ cells assessed by 3H-leucine 
incorporation. Τ cells were pre-incubated with IT in the absence 
(A) or the presence (B) of 20 mM Ш
Л
С1, followed by stimulation 
with PHÄ and a 24 hrs uptake of 3H-leucine. Inhibition of 
protein synthesis is expressed as percentage of 3H-leucine 
incorporation of untreated controls. Each point represents the 
mean of triplicate incubations from at least four experiments. 
(D) WT32-ricin A; (О) TlOl-ricin A; ( · ) WTl-ricin A; 
(*) cocktail of WT32-, T101- and WTl-ricin A. 
the individual IT resulted in a negligible inhibition (data not shown). 
These results should be interpreted with caution, in view of the low 
incorporation of 3H-leucine by normal unstimulated τ cells (ICT· cells 
incorporated maximally 1200 + 400 cpm with an average background of 300 
cpm; n=36). 
When τ cells were stimulated by PHA after treatment with IT, maximum 
leucine incorporation amounted 12,439 + 3,665 cpm (n=l6). The inhibition 
of protein synthesis occured at relative high concentrations of IT even 
with a cocktail of IT (Fig. 1A). The ID50 of the cocktail amounted 
8ХІ0-9 M (Table 1). In separate experiments it was shown that the 
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Table l. Dose-dependent cytotoxicity of IT to normal τ cells 
and potentiating effect of NH4C1. 
WT32-ricin A 
+ NH^Cl 
T l O l - r i c i n A 
+ ПЩСІ 
WTl-ricin A 
+ NH^Cl 
Cockta i l Of WT32-, 
T101-, WTl-ricin A 
+ Ш
Л
С1 
Τ c e l l s 
Ю-
7 
3χ10- 1 0 
3χ10-β 
З х Ю -
1 2 
3χ10-β 
З х Ю -
1 2 
8χ10- 9 
Ю -
1 2 
ID50- (M) 
PHA-stimulated 
Τ c e l l s 
4x l0- 9 
7х10- 1 1 
Ю -
3 
7х10- 1 Э 
З х Ю -
1 1 
ZxlO- 1 2 
З х Ю -
1 1 
2х10- 1 2 
Τ cells or PHA-stimulated Τ cells were incubated with a 
range of IT concentrations with or without 20 mM NH4C1. 
Subsequently, τ cells were cultured with ΡΗΆ for 48 hrs, 
followed by 3H-leucine uptake. PHA-stimulated Τ cells were 
labelled after IT treatment. The data represent the means of 
triplicate incubations of at least four experiments. 
'Concentration of IT required for 50% inhibition of 3H-
leucine incorporation compared with untreated controls. 
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reduction of the proliferative responses to PHA by ricin A IT measured 
with 3H-leucine incorporation was similar to reduction measured with 3H-
thymidine (data not shown). 
The cytotoxicity of ITs was greatly enhanced by the addition of 20 
mM ammonium chloride (Fig. IB). Table 2 shows the enhancing effect of 
varying concentrations ammonium chloride on WT32-ricin A. Comparable 
results were found for TlOl-ricin A and WTl-ricin A. Concentrations of 
ammonium chloride higher than 25 mM resulted in substantial inhibition 
of haematopoietic progenitor cells. The potentiating effect of ammonium 
chloride appeared to depend on the IT used: WT32-ricin-A was potentiated 
with a factor 300 in contrast to a factor 10,000 for the other IT (Table 
l). When the τ cells were incubated with free ricin Α-chain the protein 
Table 2. Potentiating effect of Ш
Л
С1 on cytotoxicity of 
WT32-ricin A. 
10-a M WT32-ricin A 3H-leucine incorporation 
+ Ш
Л
С1 (mM) (cpm + SD) 
7905 
5181 
2484 
1131 
565 
+ 
+ 
+ 
+ 
+ 
426 
651 
203 
191 
137 
(70)-
(45) 
(22) 
(10) 
( 5) 
Untreated control 11290 ± 533 (100) 
Untreated control 
+ 20 mM NHiCl 11860 + 560 (105) 
105 Τ cells were incubated with 10-" M WT32-ricin A in the 
presence of varying concentrations NH4C1, followed by stimu­
lation with PHA. Protein synthesis inhibition was measured by 
3H-leucine incorporation in triplicate incubations. 
'Numbers in parentheses represent the percentage of protein 
synthesis compared with untreated controls. Calculation were 
corrected for incorporation of unstimulated cells. The data 
represent the means + standard deviation of five experiments. 
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synthesis was only slightly reduced (maximally 10%). 
Limiting dilution assay for Τ cells 
The number of Τ cells eliminated by IT treatment was assessed by 
clonogenic assays of limiting dilutions (Table 3). The cloning 
efficiency of untreated normal Τ cells was 1.7 + 1.0 % (n=5). Τ cells 
were incubated with a concentration of IT (10-B M) causing no non­
specific cytotoxicity to haematopoietic progenitor cells. Wells with 
proliferative activity consisted of 95 + 5 % CD2/CD3 positive cells as 
determined by FCM. The cocktail of the three IT caused 83% reduction in 
the number of clonogenic Τ cells, while incubation with the 
individual IT resulted in a lower reduction. Addition of 20 iriM ammonium 
chloride during the incubation enhanced the cytotoxicity considerably 
(Table 3). The cocktail of the three IT reduced the number of 
proliferating cells by a factor of 5000 (99.98%). The reduction by the 
single IT was closely related to the percentage of antigen-positive 
cells as determined by FCM with the unconjugated MoAb. 
Table 3. Depletion of Τ cells by IT in the absence or 
presence of NH4C1 tested by limiting dilutions. 
Depletion of Τ cells (%) 
-ГОЦСІ 
0 
WT32-ricin A 43 
TlOl-ricin A 60 
WTl-ricin A 65 
Cocktail of WT32-, 
T101-, WTl-ricin A 83 99.98 
+20 mM NIUCl 
6 
97.4 
9 9 . 0 
97.5 
Different concentrations of Τ cells were incubated with l0-e 
M ricin A IT followed by a 14-day limiting dilution assay as 
described in Materials and Methods. The data represent the 
means of five experiments. 
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Fig. 2. Cytotoxicity of IT to Τ cell lines. The Τ cell lines GH1 (A), 
СЕМ (В), HPB-ALL (С), and Jurkat (D) were treated with 
different concentrations of WT32-ricin A (α), TlOl-ricin A 
(О), and WTl-ricin A ( · ), followed by a 24 hrs uptake of 3H-
leucine. Protein synthesis inhibition is expressed as percentage 
of 3H-leucine incorporation of untreated controls. Each point 
represents the mean of triplicate incubations from at least five 
experiments. 
Cytotoxicity of IT to cell lines 
In order to show that the resistance of Τ cells towards IT was not 
caused by the ineffectiveness of the IT as such,the cytotoxicity of 
the ricin Α-chain IT was tested on the Τ cell lines GHl, СЕМ, HPB-ALL, 
and Jurkat (Fig. 2). In contrast to normal Τ cells protein synthesis 
of all lines was reduced effectively in relation to the antigen density 
for the particular IT (Table 4). Effective cytotoxicity could also be 
shown by the fast kinetics of protein synthesis inhibition in all cell 
lines with a high antigen density for the particular IT. Inhibition of 
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Table 4. Antigen density of Τ cell lines and Τ cells. 
Antigen density (average no. of molecules 
bound per cell χ IO-3 + SD) 
CD (МоАЬ) 
CD3 (WT32) 
CD5 m o n 
CD7 (WTl) 
GH1 
6+2 
32+0 
175+25 
СЕМ 
0+0 
25+1 
63+3 
HPB-ALL 
185+12 
64+3 
20+1 
J u r k a t 
73+9 
52+6 
106+5 
Τ c e l l s 
56+13 
22+1 
48+7 
Antigen density is measured by binding analysis of 125Іоаіпе-1аЬе11еа 
МоАЬ at 40C. The data represent the means + standard deviation of three 
independent measurements. 
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Fig. 3. Cytotoxicity of IT to PHA-stimulated Τ cells. Normal Τ cells 
were stimulated by PHA and incubated with IT in the absence (A) 
or the presence (B) of 20 mM NH4C1, followed by a 24 hrs
 3H-
leucine incorporation. Inhibition of protein synthesis is 
expressed as percentage of 3H-leucine incorporation of untreated 
controls. Each point represents the mean of triplicate 
incubations from at least four experiments. 
(D) WT32-ricin A; (o) TlOl-ricin A; (·) WTl-ricin A; 
(*) cocktail of WT32-, T101- and WTl-ricin A. 
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50% of the 3H-leucine incorporation by l0-e M WTl-ricin A in GH1 was 
achieved within 1 hr, by TlOl-ricin A in Jurkat within 3 hrs, and by 
WT32-ricin A in HPB-ALL within 5 hrs. 
Antigen density and internalization of CD antigens on Τ cells and Τ 
cell lines 
Comparison of the average antigen density on Τ cells and Τ cell lines 
(Table 4) did not explain the different sensitivities of the cell 
populations. CiM and GH1 expressed CD5 in similar amounts to normal Τ 
cells, but identical protein synthesis inhibition was obtained at 300-
and 1000-fold lower concentrations of TlOl-ricin A, respectively. 
The ability of normal Τ cells to internalize antibody was comparable 
with the internalization capacity of τ cell lines (F. Preijers et al., 
unpublished observations). The percentages of internalization into Τ 
cells were 46% for WT32, 34% for T101 and 74% for WT1. The relative 
lower sensitivity of normal τ cells compared to Τ cell lines is 
apparently not caused by a lower antigen density or a lower capacity to 
internalize the IT. 
Cytotoxicity of IT to PHA-stinnilated Τ cells 
When τ cells were stimulated with PHA prior to incubation with IT, 
higher cytotoxicity to Τ cells could be obtained, varying between 25-
fold for WT32-ricin A, 30-fold for TlOl-ricin A, and 1000-fold for WTl-
ricin A (Fig. ЗА and Table 1). When the incubation with IT was performed 
in the presence of 20 mM Ш
Л
С1, the killing of unstimulated and 
stimulated Τ cells became comparable (Figs. IB and 3B). 
Cytotoxicity of IT to bone marrow progenitor cells 
To examine the inhibiting effect of IT on haematopoietic stem cells, 
bone marrow samples were cultured after treatment with ίο-8 M IT with or 
without 20 mM ammonium chloride. The treatment of bone marrow cells with 
IT in the absence of Ш
Л
С1 did not affect the plating efficiency of CFU-
GM and BFU-E (Table 5). In the presence of 20 mM Ш
Л
С1 only a slight 
reduction was observed. 
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Table 5. Influence of IT and КН
Л
С1 on haematopoietic 
progenitor cells. 
Incubation of 
bone marrow cells 
WT32-ricin A 
TlOl-ricin A 
WTl-ricin A 
Cocktail of WT32-, 
T101-, WTl-ricin A 
NH»C1 
WT32-ricin A + NH4C1 
TlOl-ricin A + NH4C1 
WTl-ricin A + NH4C1 
Cocktail of WT32-, 
T101-, WTl-ricin A + NH4CI 7 2 + 8 7 6 + 8 
CFU-
(% + 
99 + 
102 + 
102 + 
94 + 
88 + 
75 + 
82 + 
87 + 
-GM 
SD) 
9 
4 
8 
10 
10 
6 
13 
10 
BFU-E 
(% 
99 
94 
97 
98 
72 
79 
63 
75 
+ SD) 
+ 10 
ί 13 
+ 14 
± 15 
+ 10 
+ 15 
+ 13 
+ 12 
10е Bone marrow cells were incubated with 10-8 M IT in the 
absence or presence of 20 mM NH^Cl. Thereafter clonogenic 
assays CFU-GM and BFU-E were performed. Numbers in the table 
represent the mean percentages + standard deviation of 
colonies of untreated controls in five experiments. 
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DISCUSSIOM 
In this study we compared the cytotoxicity of three anti-T cell IT: 
WT32-ricin A (anti-CD3), TlOl-ricin A (anti-CD5), and WTl-ricin A (anti-
CD7), separately or as a cocktail, to normal τ cells and to Τ cell 
lines. Clonogenic assays and protein synthesis inhibition assays were 
used to measure the cytotoxic effects on the target cells. 
The three IT, separately or as a cocktail, did not appear to be 
very cytoxic to normal Τ cells, whereas cytotoxicity to Τ cell lines was 
considerable and comparable to data reported by others [4,16]. The low 
cytotoxicity of IT to normal Τ cells observed by us confirmed the 
findings of other studies with anti-CD5-ricin A IT [11,24], but 
contrasted with the data of Martin et al. [14]. They observed that 
anti-CD3-ricin A IT at a concentration of l.7xl0-e M inhibited the 3H-
leucine incorporation by 81%. In our hands even a cocktail of anti-CD3, 
anti-CD5, and anti-CD7 ricin A conjugates induced not more than 50% 
protein synthesis inhibition with 8xl0-9 M IT. Recently we have 
demonstrated a relationship between cytotoxicity of IT and the amount of 
internalized ITs into Τ cell lines [20a]. In this latter study we were 
able to show that internalization of IT into Τ cell lines and into 
normal Τ cells was equal. Therefore, it has to be concluded that the low 
susceptibility of normal Τ cells to IT must be due to an intrinsic 
property of these cells and not to a •different internalization of the 
IT. This hypothesis is supported by the observation that stimulation of 
normal Τ cells by ΡΗΆ prior to incubation with IT increased the 
susceptibility considerably. Since PHA activates protein synthesis the 
low level of protein synthesis in unstimulated Τ cells may be 
responsible for the limited sensitivity to IT. 
When 20 mM ammonium chloride was added in combination with the IT, a 
high cytotoxicity to unstimulated Τ cells was observed. This 
cytotoxicity is in agreement with data from other investigators with 
ricin A IT [10,11,14,21,24] and comparable to the cytotoxicity of intact 
ricin IT [12,22,32,34]. The enhancement by ammonium chloride was similar 
for stimulated and unstimulated Τ cells. The cocktail showed better and 
more consistent cytotoxicity than the individual IT. Ammonium chloride 
did not influence the internalization process of the IT [2]. Ammonium 
chloride does, however, affect several intracellular processes related 
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to the handling of internalized IT. Figura et al. [5] found, after 
addition of ammonium chloride, a strong increase in the amount of newly 
synthesized lysosomal enzymes released from the cell in proportion to 
the amount delivered to the lysosomes. Furthermore, ammonium chloride 
can affect the activity of lysosomal enzymes by increasing the lysosomal 
pH [17]. In addition, the delivery of the IT to the lysosomes appeared 
to be delayed in the presence of ammonium chloride, which may decrease 
the lysosomal degradation of ricin A [2,21]. 
Our results show that the anti-T cell IT WT32-ricin A, TlOl-ricin 
A, and WTl-ricin A in a concentration of 10-s M in the presence of 20 mM 
NH4CI have no influence on haematopoietic progenitors (CFU-GM and BFU-
E). Similar minor inhibitory effects of haematopoietic progenitor cells 
have been described by others [11,14,24], whereas in that concentration 
Τ cells are eliminated by a factor of more than 5000, enabling in vitro 
depletion of human Τ cells from bone marrow intended for 
transplantation. Further experiments have to be carried out to determine 
the best combination of IT for the optimal elimination of Τ cells 
without the introduction of early graft failure or graft rejection 
after initial haematopoietic reconstitution [13,19]. Besides, the CD3-
negative large granular lymphocyte population, which possibly have an 
anti-leukaemic effect [8], may not be affected. 
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Авзталст 
Graft-versus-host disease (GVHD) after allogeneic bone marrow 
transplantation (BMT) is initiated by immunocompetent Τ cells present in 
the graft. Selective elimination of distinct T-cell subsets or a 
sufficient, but not complete T-cell depletion, might abolish severe GVHD 
without graft rejection and loss of the anti-tumour potential. In this 
study we analysed the efficacy of different monoclonal antibodies (MoAb) 
WT32 (CD3), 0KT4 (CD4), T101 (CD5), WT1 (CD7), and WT82 (CD8) with 
respect to their cytotoxicity to Τ cells either as immunotoxin (IT) or 
in combination with complement. The cytotoxic potential was assessed by 
protein synthesis inhibition and clonogenic assays. The ricin A 
conjugated MoAb exerted only a minor effect on blood or bone marrow Τ 
cells, although they were highly inhibitory to T-cell lines. However, in 
the presence of 20 mM ammonium chloride IT directed against CD3, CD5, 
and CD7 were highly cytotoxic. IT directed against CD4 and CD8 were less 
effective, due to a low internalization. The complement-mediated 
cytotoxicity was efficient for all antigens used. 
The natural killer (NK) activity, as measured by cytotoxicity to 
K562, was hardly depressed by anti-CD3, anti-CD4, anti-CD5, and anti-
CD8, but was eliminated by anti-CD7. All procedures used had only a 
minimal effect on haematopoietic progenitors as measured by CFU-GM and 
BFU-E assays. 
We concluded that, although the T-cell population can be eliminated 
with the combination of anti-CD3, anti-CD5, and anti-CD7 antibodies plus 
complement, IT with 20 mM NH4C1 appear to kill higher amounts of Τ 
cells. Selective elimination of CD4- and CD8-positive cells is 
effectively obtained by MoAb with complement. 
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ШТКСЮЦСТІШ 
Graft-versus-host disease (GVHD) is one of the major causes 
of morbidity and mortality following allogeneic bone marrow 
transplantation (ВМГ). It occurs in 30-60% of patients receiving HLA-
identical sibling bone marrow, with a fatal outcome in approximately 50% 
of severely affected patients [37,40]. Several studies in rodents 
[5,10,13,16] have provided evidence that immunologically competent 
mature Τ cells present in the graft are responsible for the initiation 
of acute GVHD. Removal of Τ cells from the transplant reduces and even 
frequently prevents GVHD in man [8,12,22,27,29,42]. Although the minimal 
amount of Τ cells responsible for GVHD is not yet known and therefore 
complete depletion of Τ cells is sometimes propagated, such a drastic 
approach may increase the risk of a relapse [1] and may result in a 
delayed reconstitution of immune functions and increases the risk of 
graft rejection [20,25]. Preferably, Τ cells must be depleted from the 
transplant without concomitant loss of the subpopulations with anti-
leukaemic capacity [6,11,41]. Depletion of immune competent Τ lymphocy­
tes can be achieved by various methods, e.g. counterflow centri fugation 
[4?], E-rosetting with or without prior lectin separation [7,9,29] or by 
means of monoclonal antibodies (MoAb) and rabbit complement (RC) 
[12,15,20,22,27]. Although not all methods are specific for the 
elimination of subpopulations, they have been applied successfully to 
deplete Τ cells from donor bone marrow intended for BMT. More recently, 
immunotoxins (IT) have been utilized to eliminate Τ cells in vitro 
because of their highly selective and potent cytotoxicity. Several IT 
have been prepared by conjugation of the highly toxic phytolectin ricin 
or its toxic A-cham to MoAb [8,21,26,28,32,38,39]. Investigations to 
determine the maximum elimination of malignant Τ cells have demonstrated 
that ricin A IT in the presence of ammonium chloride [3] are very 
effective when the target cells possess a sufficient density of the 
particular antigen on the cell membrane [4,23] and have the capacity to 
internalize the IT into the cell (F. Preijers et al., unpublished 
observations). 
Recently we showed that normal Τ cells had a low susceptibility to 
ricin Α-chain IT directed against CD3, CDS and CD7 compared with Τ cell 
lines. The efficacy could be improved by addition of 20 mM ammonium 
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Chloride [26]. These findings underlined the importance of preclinical 
investigations to assess the conditions that lead to an optimal 
elimination of Τ cells by different cytotoxic agents. In the present 
study we compared the cytotoxic efficacy of ricin Α-chain IT directed 
against CD3 (WT32), CD4 (0KT4), CDS (T101), CD7 (WT1), and CD8 (WT82) on 
normal Τ cells with the cytotoxicity of the complement-mediated lysis by 
the same MoAb. Moreover, the influence of these cytotoxic agents on Ж 
activity was studied. 
MATERIALS AND METHODS 
Isolation of τ lymphocytes 
Peripheral blood mononuclear cells were isolated from the buffy coat and 
enriched for τ cells by nylon wool filtration as described previously 
[26]. The percentage of T cells in the obtained cell suspension was 
determined by flow cytometry (FCM). Cells were suspended in RPMI 1640 
supplemented with 10% heat inactivated fetal calf serum (FCS) (HyClone 
Labs, Logan, Utah), 2 mM glutamine, 1 mM sodium pyruvate and gentamycin 
(50 ug/ml). 
Bone marrow τ cells were isolated from aspirated donor bone marrow 
intended for allogeneic bone marrow transplantation by centri fugation 
over Percoli (Pharmacia, Uppsala, Sweden) gradients and counterflow 
centri fugation, as described previously [42,43]. The percentage of τ 
cells was determined by FCM. 
Monoclonal antibodies, complement and synthesis of IT 
Murine anti-human Τ cell MoAb: WT1, anti-CD7 [36]; WT32, anti-CD3 [35]; 
WT82, anti-CD8 [35]; 0KT4, anti-CD4 [17]; andTlOl, anti-CD5 [30] were 
of the IgG2a isotype and complement fixing. MoAb were purified using 
Staphylococcus aureus protein A coupled to Sepharose (Pharmacia). 
Serum of 4 to 6- week-old New Zealand-White rabbits was used as 
complement (RC) source. Sera of all rabbits were tested separately at 
specific and nonspecific lysis of mouse spleen cells and human T-cell 
lines. Sera with optimal cytotoxicity were pooled, snap froozen and 
stored at -70oc until use. 
Purified ricin A was kindly provided by Dr F.К. Jansen (Centre de 
68 
Recherches Clin Midy-Group Sanofi, Montpellier, France). MoAb were 
coupled to ricin A-chain with SPDP (Pharmacia). TlOl-ricin A was kindly 
donated by Dr P. Casellas (Centre de Recherches Clin Midy). Free 
antibody and free A-chain were removed by Sephacryl S200 gel filtration. 
The molar ratio of the A-chain and the antibody appeared to vary between 
1 and 1.8. By FCM and enzyme linked immunosorbent assay (ELISA) it was 
proven that the antibody-binding activity was preserved after 
conjugation. The non-specific cytotoxicity of all conjugates was tested 
on cell lines which did not express the relevant antigen. 
IT- or coniplement-iBecLiated cytotoxicity to Τ cells 
Cytotoxicity of IT to Τ cells in the absence or presence of 20 mM NH„C1 
was determined by inhibition of 3H-leucine incorporation after an 
incubation for 24 hrs and stimulation by phytohaemagglutinin (PHA) for 
48 hrs as described previously [26]. In experiments to determine the 
time dependency of the cytotoxicity, cells were incubated for 1, 2, 3, 
or 5 hrs. To determine complement-mediated cytotoxicity, cells were 
incubated for 23 hrs to synchronize experiments, prior to preincubation 
with varying concentrations of MoAb plus 1:6 vol/vol RC for 1 hr. 
Incubation with RC for more than 1 hr caused non-specific cytotoxicity. 
The cytotoxicity was expressed as a percentage of the inhibition of the 
3H-leucine incorporation of PHA-stimulated cells not treated with IT, 
incubated with or without ammonium chloride, or MoAb and complement, 
corrected for the background value obtained from cells not stimulated 
with PHA. 
Cytotoxicity to bone marrow Τ cells was determined by preincubation 
of 107 cells/ml in 50 ml culture flask (Costar) in culture medium. Cells 
were supplemented with varying concentrations of ricin A-chain IT with 
or without 20 mM ammonium chloride during 24 hrs, or with varying 
concentrations of MoAb and RC (1:6 vol/vol) for 1 hr after culturing 
for 23 hrs in culture medium. Protein synthesis inhibition was 
determined as described before. 
Limiting dilution assay for Τ cells 
Clonogenic assays of limiting Τ cell dilutions were performed as 
described previously [26]. Briefly, Τ cells were incubated with IT (l0-e 
M) with or without 20 mM NH4C1 for 24 hrs, or with MoAb (10 pg/ml: 
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6.7χ10-β M) plus RC (1:6 vol/vol) for 1 hr at 37°C. Cells were washed 
and suspended in RPMI 1640 (DM) supplemented with 15% FCS, 20% vol/vol 
interleulcin-2 (IL-2; Lymphocult, Biotest, Fairfield, NJ, USA), 15% PHA-
leukocyte-conditioned medium (PHA-LCM), 50 цд/ті PHA, and 10 ng/ml 
phorbol l2-0-tetradecanoylphorbol-13-acetate (TPA) and seeded in 96-
well round-bottom microtiter plates. After incubation for 14 days 
proliferative lymphocytes were scored. Cloning efficiency was determined 
by the minimum chi-square method from the Poisson distribution between 
cells seeded per well and the logarithm of the percentage of negative 
wells [34]. 
IT- or complement-mediated cytotoxicity to normal bone marrow 
progenitor cells 
Bone marrow was obtained from patients undergoing cardiac surgery after 
informed consent. Erythrocytes and mature granulocytes were removed by 
centrifugation on a gradient of Ficoll-Hypaque (1.077 g/ml). Cells 
(106/ml) were incubated with IT or MoAb and RC as described for the 
limiting dilution assays. After this incubation cells were washed and 
the reduction in bone marrow progenitors was determined in clonogenic 
assays of granulocyte/macrophage colony-forming cells (CFU-GM) and 
erythroid burst-forming cells (BFU-E) as described previously [44]. 
Natural Xiller activity after Τ cell depletion 
Lymphocytes were isolated from peripheral blood by Ficoll (1.077 g/ml) 
centrifugation. Cells in a concentration of 4xl06/ml were incubated in 
sealed tubes with 10-8 M ricin A IT in the presence of 20 mM Ш
Л
С 1 for 2 
hrs (see Results) or 10 цд/ті MoAb with RC for 1 hr. Subsequently, the 
cells were washed and incubated for 18 hrs with 500 units/ml recombinant 
IL-2 in culture medium to increase NK activity [18]. Then cells were 
washed and placed in 96-well U-bottomed plates in serial dilutions to 
yield an effector to target ratio of 50:1, 25:1, 12.5:1, and 6.25:1 in 
100 μΐ culture medium. slCr-labelled K562 blasts were added in a 
concentration of 10V100 μΐ. After 3.5 hrs of incubation at 370C, the 
cell mixtures were centrifuged and radioactivity of 100 μΐ supernatant 
was measured. 
Maximum release was determined from K562 cells treated in culture 
medium with 10 μΐ saponin. Spontaneous lysis was measured from K562 
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incubated with culture medium only. NK activity was expressed as 
percentage "^Cr-release by NK-mediated lysis: 
% 51cr-release =51Cr-release by NK - spontaneous slCr-release xlOO 
51Cr-release max. - spontaneous sicr-release 
RESULTS 
PeriiÄieral blood Τ cell population 
The enriched lymphocyte population was analyzed by FCM. The cell 
population obtained by Ficoll gradient showed two scatter clusters: the 
lymphocyte area consisting of 68% cells and the monocyte area 
consisting of 23% cells. This cell suspension contained 70% С02* and 
64% CD3^ cells. After nylon wool filtration the lymphocyte area 
contained 91% of the nucleated cells. This cell population contained 90% 
CD2*, 82% CD3~, 92% CDS*, and 79% CD7* cells with a T4/T8-ratio Of 1.2. 
Nylon wool filtrated cells were used in all experiments with peripheral 
blood cells. 
IT- or complanent-mediated protein synthesis inhibition of peripheral 
blood τ cells 
Cytotoxicity of the anti-T cell MoAb WT32 (CD3), OKT4 (CD4), T101 (CD5), 
WT1 (CD7) and WT82 (CD8), conjugated with ricin Α-chain, to blood Τ 
cells was compared with complement- mediated cytotoxicity of these MoAb. 
Τ cells were incubated with varying concentrations between Ю-"7 and 
ΙΟ-
12
 M of IT or MoAb with RC. Results of T-cell treatment with the 
highest concentration of IT that caused negligible non-specific 
cytotoxicity (10-e M) or MoAb (10 цд/ті: 6.7xl0-e M) with RC are shown 
in Fig. 1. Ammonium chloride as such did not inhibit the protein 
synthesis, whereas incubation with RC resulted in a slight reduction 
(8%). Ricin Α-chain conjugates did not effectively inhibit the protein 
synthesis, but addition of 20 ntM ammonium chloride resulted in a strong 
enhancement of the cytotoxicity of anti-CD3, anti-CD5, and anti-CD7 IT. 
A cocktail of these IT almost completely inhibited the protein 
synthesis. The RC-mediated cytotoxicity of anti-CD3, anti-CD5, and anti-
CD? was comparable to that of the corresponding IT. 
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Fig. 1. Cytotoxicity of MoAb conjugated to ricin A or in combination 
with RC to blood Τ cells. Τ cells were incubated with ΙΟ-8 M IT 
in the absence or the presence of 20 шМ Ш
Л
С1 or with 10 цд/ші 
MoAb with 1:6 vol/vol RC, followed by stimulation with PHA and 
a 24 hrs incorporation of 3H-leucine. Inhibition of protein 
synthesis is expressed as a percentage 3H-leucine incorporation 
by untreated control cells. Each point represents the mean of 
triplicate incubations from minimum of five experiments and had 
a standard deviation of less than 10 %. 
In contrast to the limited cytotoxicity of anti-CD4 and anti-CD8 
ricin A IT with 20 mM Ш
Л
С1, treatment of cells with these MoAb and RC 
resulted in a protein synthesis inhibition according to the percentage 
of antigen positive Τ cells, while a cocktail of these MoAb plus RC 
inhibited the protein synthesis in nearly all Τ cells. 
Limiting dilutions of peripheral blood Τ cells 
The absolute depletion of Τ cells was determined by colony growth in 
limiting T-cell dilutions. The extent of T-cell depletion was determined 
from the cloning efficiency of native cells (Table 1). The cloning 
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Table 1. Cytotoxicity to Τ cells by IT with or without Ш
Л
С1 
or by MoAb with RC tested by limiting dilutions. 
Factor of T-cell reduction 
-
CD3 (WT32) 
CD4 (0KT4) 
CD5 (T101) 
CD7 (WT1) 
CD8 (WT82) 
Cocktail of 
T101, WT1 
Cocktail of 
WT82 
WT32, 
OKT4, 
IT 
1.0 
1.8+1.2 
1.2+0.2 
2.5+1.0 
2.8+0.4 
1.0+0.0 
5.8+4.0 
2.8+0.3 
IT + NH4C1 
1.1+0.1 
38+14 
2.5+1.0 
100+35 
40+14 
1.3+0.3 
5000+670 
5.8+1.0 
MoAb + RC 
1.3+0.7 
61+30 
5.9+1.0 
252+86 
31±13 
2.0+0.5 
167+51 
63+10 
Different concentrations of τ cells were preincubated with 10-8 M 
ricin A IT in the absence or the presence of 20 mM ammonium 
chloride or with 10 цд/ті MoAb plus RC, followed by a 14-day 
limiting dilution assay as described in Materials and Methods. 
Data represent the mean + standard deviation of five 
experiments. 
efficiency of untreated cells amounted 1.7 + 1.0 % (n=5). These cells 
were cultured under identical conditions as treated cells. The delay in 
time, due to the preincubation explains the relatively low cloning 
efficiency. Wells with proliferating lymphocytes consisted of 95% 
CD2--/CD3* cells, determined by FCM. Ricin Α-chain IT in the absence of 
ammonium chloride caused only a slight reduction in the number of 
proliferative Τ cells, in contrast to appropriate IT in the presence of 
20 mM ammonium chloride or MoAb with RC. Although the reduction by ricin 
A IT directed against CD3, CD5, and CD7 in the presence of 20 mM 
ammonium chloride was comparable with RC-mediated reduction by the MoAb, 
73 
the non-specific cytotoxicity of RC was higher than that caused by 20 mM 
ammonium chloride. A cocktail of the three IT directed against CD3, CD5, 
and CD7 with ammonium chloride appeared to reduce a higher percentage of 
the T-cell population (99.98%) than a combination of the free MoAb with 
RC (99.4%). These results show that a cocktail of ricin Α-chain IT 
directed against CD3, CD5, and CD7 is very effective for the elimination 
of nearly all Τ cells. 
ITs directed against CD4 and CD8 had hardly any effect. In contrast, 
CD4* and CDS* Τ cells could be fairly completely eliminated by the 
relevant MoAb with RC. The cocktail of these MoAb plus RC reduced 98.4% 
of the T-cell population (Table 1). 
δ so 
υ 
60 
Fig. 2. Time dependent cytotoxicity of IT to blood Τ cells. Τ cells 
were incubated with varying concentrations of a cocktail of 
WT32-ricin A, TlOl-ricin A, and WTl-ricin A in the presence of 
20 mM ГОЦСІ for 1 ( · ), 2 ( о ), 3 ( • ), 5 ( a ) , and 24 ( • ) 
hrs, followed by stimulation with PHA and 24 hrs incorporation 
of 3H-leucine. For additional legends see Fig. 1. Each point 
represents the mean of triplicate incubations from three 
experiments. 
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Influence of incubation period on cytotoxicity of IT 
In our experimental setting the coclctail of WT32-ricin A, TlOl-ricin A 
and WTl-ricin A appeared to be more effective than the cocktail of MoAb 
with RC. However, cells were incubated for 24 hrs with IT in contrast to 
1 hr with MoAb plus RC. In order to make both types of experiments 
comparable, the influence of incubation time on the cytotoxicity of IT 
was determined. Cells were treated for l, 2, 3, or 5 hrs with the 
cocktail of the three IT with 20 mM Ш
Л
С1. An incubation of 2 hrs or 
more resulted in the same protein synthesis inhibition as effected by 24 
hrs incubation (Fig. 2). These results suggest that an incubation for 2 
hrs with a cocktail of IT is adequate for an optimal cytotoxicity. 
100 
С 80-
ы 
IT 
IT+NH4C1 
¡ \ MoAb+RC 
CD3 CD4 CDS CD7 CDS CD3,5,7 CD4,8 
Fig. 3. Cytotoxicity of MoAb conjugated to ricin A or with RC to bone 
marrow Τ cells. Τ cells were isolated from bone marrow by 
elutriation and preincubated with 10-s M IT with or without 20 
mM NH4CI or with 10 \iq/ml MoAb with 1:6 vol/vol RC in bulk 
culture of 107 cells/ml, followed by stimulation with PHA and 
24 hrs incorporation of 3H-leucine. For additional legends see 
Fig. 1. 
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Table 2. Influence of IT and NH4C1 or MoAb with RC on 
hematopoietic progenitor cells. 
Recovery (% + SD) 
Incubation of 
bone marrow cells CFU-GM BFU-E 
Cocktail of WT32-, 
T101-, WTl-ricin A 
Ш
Л
С1 
WT32-ricin A + NH4C1 
Т101-ГІСІП A + NH4C1 
WTl-ricin A + Ш
Л
С1 
Cocktail of WT32-, 
T101-, WTl-ricin A + Ш
Л
С1 
RC 
WT32 + RC 
OKT4 + RC 
T101 + RC 
WT1 + RC 
WT82 + RC 
Cocktail of WT32, 
T101 and WT82 + RC 
Cocktail of 0KT4 
and WT82 + RC 
94 
88 
75 
82 
87 
72 
98 
88 
96 
91 
91 
90 
90 
99 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
10 
10 
6 
13 
10 
8 
2 
10 
4 
6 
8 
7 
6 
1 
98 
72 
79 
63 
75 
76 
98 
96 
98 
98 
95 
92 
89 
99 
± 15 
+ 10 
± 15 
± 13 
± 12 
± 8 
+ 5 
+ 5 
+ 2 
+ 3 
+ 5 
± 8 
± 8 
+ 3 
106 Bone marrow cells were preincubated with 10-8 M IT in the 
absence or presence of 20 mM Ш
Л
С1 for 24 hrs or with 10 цд/ті 
MoAb plus RC for 1 hr. Thereafter clonogenic assays CFU-GM and 
BFU-E were performed. Numbers in the table represent the mean 
percentage + standard deviation of colonies scored with 
untreated controls in five experiments. 
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IT- or ccHnplanent-ieediated cytotoxicity to bone marrow Τ cells and 
haematopoietic progenitor cells 
Bone marrow cells were treated on a large scale with IT and Ш
Л
С 1 or 
with MOAb and RC under conditions identical to donor bone marrow 
intended for transplantation. The bone marrow cell population contained 
82% CD2*, 65% CD3 +, 70% CDS*, and 72% CD7* cells. Inhibition of protein 
synthesis in bone marrow τ cells (Fig. 3) was comparable to that of 
blood Τ cells (Fig. 1). A cocktail of WT32-ricin A, TlOl-ricin A and, 
WTl-ricin A in the absence of ammonium chloride slightly reduced the 
protein synthesis (35%), while these IT in the presence of 20 mM 
ammonium chloride, similar to the cocktail of MoAb with RC, reduced the 
protein synthesis completely. 
The non-specific IT- or complement-mediated cytotoxicity to 
haematopoietic progenitor cells was determined by clonogenic assays for 
CFU-GM and BFU-E. The treatment with IT or MoAb with RC hardly affected 
the plating efficiency of CFU-GM and BFU-E (Table 2). These results 
suggest that depletion of normal Τ cells from bone marrow by a selected 
cocktail of IT in the presence of 20 mM NH4C1 or by MoAb plus RC is 
highly selective. 
Influence of IT and MoAb plus RC on NK activity 
The decrease of NK activity in the T-cell population by treatment with 
IT or MoAb with complement was tested on lymphocytes present in the low 
density fraction of a Ficoll separation to avoid any loss of NK-cell 
activity in the nylon wool column. The reduction of Ж activity by 
varying effector to target ratios is shown in Figure 4. Preincubation 
with 20 mM ammonium chloride or 1:6 (vol/vol) RC alone did not influence 
the NK activity (NK activity of untreated cells is not shown). Anti-CD7, 
as IT or with complement, caused an almost complete reduction of the NK 
activity. Anti-CD3 and anti-CD5, as IT or with RC, did not measurably 
decrease the slCr-release. Anti-CD4 and anti-CD8 with RC had no 
influence on the NK activity. These results suggest that the NK-cell 
activity is located in the CD3/CD4/CD5/CD8-negative and CD7-positive 
cell population. 
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4. Influence of IT and complement-mediated cytotoxicity of MoAb 
to NK activity. Blood Τ cells were preincubated with 10-β M IT 
in the presence of 20 mM NH4C1 (A) or with 10 цд/ті MoAb and 
1:6 vol/vol RC (B) for 2 hrs and 1 hr respectively, prior to an 
incubation for 18 hrs with 500 U/ml recombinant IL-2. NK 
activity was based on the percentage of maximal 51Cr-release of 
K562 and corrected for the spontaneous 51Cr-release. The line 
without symbols represents the preincubation with NH^Cl and RC, 
respectively. Values are the results of one representative 
experiment out of three. 
(•) anti-CD3; (Δ) anti-CD4; (•) anti-CDS; (·) anti-CD7; 
(D) anti-CD8; (O) anti-CD3-CD5-CD7. 
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DISCUSSIOM 
Various methods can be used for the elimination of Τ cells from bone 
marrow. Monoclonal antibodies conjugated to ricin Α-chain or MoAb in 
combination with RC appeared to be very efficient for this purpose 
[12,14,15,20-22,27,28]. In the present study we compared the 
cytotoxicity of ricin A conjugates and free MoAb in combination with RC 
directed against CD3, CD4, CD5, CD7, and CD8, separately or in 
combination. Cytotoxicity was determined by protein synthesis 
inhibition and by clonogenic assays. As found previously [26], ricin A 
conjugates appeared to be ineffective against normal Τ cells. Even a 
cocktail of ricin A IT directed against CD3, CD5 and CD7 removed only 
84% of the Τ cells (Table 1). But in the presence of 20 mM ammonium 
chloride, these ITs eliminated all antigen-positive Τ cells. Ricin A IT 
and MoAb with RC killed Τ cells to comparable extent according to the 
findings of Martin et al. [21]. 
Ricin A IT directed against CD4 and CD8, however, showed a low 
cytotoxicity to normal Τ cells in the presence of ammonium chloride, 
due to a poor internalization of the target antigen (F. Preijers, 
unpublished observations). This minimal internalization may be related 
to the binding of IT to a specific epitope. Therefore, the efficacy of 
three different anti-CD8 ricin A IT was determined and a low 
cytotoxicity was found for all three IT (F. Preijers, unpublished 
observations). Low cytotoxicity of anti-CD8-ricin A to Τ cells was also 
found by Katz et al. [14] using a different anti-CD8 antibody. 
Furthermore, when we tested four other IT directed against the CD3/T 
cell receptor complex apart from WT32-ricin A, cytotoxicity of all 
tested IT was similar (F. Preijers, unpublished observations) and 
comparable to the data of others [21]. This again indicates that 
epitope-specificity is apparently not an important factor for the 
efficacy of an IT. With anti-CD4 or anti-CD8 antibodies, RC-mediated 
cytotoxicity was more effective than IT. A cocktail of these two MoAb 
plus RC killed 98.4% of the Τ cells, which is consistent with the 
percentage CD4* or CD8* cells in the cell suspension. 
The individual IT directed against CD3, CDS, and CD7 in the presence 
of ammonium chloride exert a cytotoxicity comparable to the 
corresponding MoAb and RC. A cocktail of these ITs eliminated almost 
79 
all Τ cells (residual Τ cells: 0.02%) in contrast to 0.6% residual τ 
cells after depletion with a cocktail of MoAb and RC. An effective 
cytotoxicity of anti-CD4 and anti-CD8 MoAb in a cocktail has only been 
observed for RC-mediated kill (this study and Refs. 12,19,20,27). 
Therefore, anti-CD4 and anti-CD8 IT should not be incorporated in a 
cocktail of anti-T cell IT. 
A high degree of depletion of T-cell subpopulations seems to be 
necessary, particular for the prevention of GVHD after BMT of HLA-non-
• identical bone marrow. We determined the IT- and complement-mediated 
cytotoxicity to bone marrow Τ cells under circumstances comparable to 
those of donor bone marrow intended for transplantation; i.e. large 
volume and high cell concentration. The cytotoxicity to bone marrow τ 
cells of both methods was similar to the results obtained with blood Τ 
cells, whereas only a marginal inhibition of hematopoietic progenitor 
cells was observed. Earlier experiments with IT were performed with an 
incubation time of 24 hrs. Since a shorter time would be a prerequisite 
for clinical applicability, we also studied shorter incubations with IT 
and found that a 2-hr incubation yields the same cytotoxicity. 
Although the exact degree of T-cell depletion to prevent GVHD is 
unsettled, removal of excessively high numbers of Τ cells may result in 
a delayed reconstitution, failure of engraftment, or even rejection of 
the graft [25,31]. Moreover, the data of Van der Weiden, et al. [41] 
showed that transplant recipients who developed significant GVHD had a 
decreased risk of leukemia recurrence. The graft-versus-leukemia 
potential of the donor marrow will be compromised by complete T-cell 
depletion [1,22], resulting in a higher risk of leukaemia relapse. 
Although the precise cell subpopulation responsible for the anti-
leukaemia effect is unknown, NK cells may contribute to this effect. 
Therefore, selective elimination of T-cell subpopulations responsible 
for GVHD without a loss of NK activity may improve the outcome after 
transplantation. We assessed the reduction of NK activity by the various 
combinations of IT and MoAb with RC. Anti-CD3 and anti-CD5 did not 
inhibit the NK activity, confirming the findings of Uckun et al. [38]. 
Moreover, no inhibition of NK activity was found with anti-CD4 and anti-
CD8, whereas anti-CD7 inhibited NK cells effectively. These findings 
suggest that the NK population is CD3-negative, which may imply that 
this population consists of large granular lymphocytes (LGL) [2]. 
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Incubation with high concentrations of IL-2 alone can predominantly 
activate a LGL population with CD3/CD4/CD8-negative and CD16/CD25-
positive phenotype, with a minimal stimulation of τ cells [24,33J. 
We conclude that ricin Α-chain conjugates directed against CD3, 
CD5, and CD7, in a cocktail or separately, are very effective for the 
elimination of all T-cell subpopulations. However, the presence of anti-
CD? IT results also in the elimination of NK-cell activity in bone 
marrow intended for transplantation. These findings suggest that anti-
CD? should be omitted from cocktails intended to deplete donor bone 
marrow to prevent GVHD in order to maintain cells with potential anti-
leukaemic activity in the graft. Besides, not all τ-cell antigens 
represent targets through which effective kill can be achieved by ricin 
A IT due to the low internalization of some antigens (CD4 and CD8). 
These T-cell subpopulations can selectively be eliminated by MoAb and 
RC. Selective elimination of Τ lymphocytes with GVH reactivity, and 
preservation of populations with anti-leukaemic activity may improve the 
clinical outcome after allogeneic BMT. 
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ABSTRACT 
With the perspective of bone marrow purging in autologous 
transplantation, we investigated the cytotoxicity of the anti-T cell 
immunotoxin (IT) WTl-ricin A (anti-CD7) to malignant Τ cells obtained 
from patients with Τ cell acute lymphoblastic leukaemia or lymphoma. The 
cytotoxic efficacy of IT was based on the extent of protein synthesis 
inhibition. Cytotoxicity of IT to malignant Τ cells showed a dependency 
on antigen density comparable to the Τ cell lines GH1, СЕМ, Jurkat, 
HSB-2 and HPB-ALL and was enhanced considerably in the presence of 6 
mM ammonium chloride. The ultimate proof of cell kill can only be 
obtained from clonogenic assays, however culturing of malignant τ cells 
was not feasible. Therefore these assays were performed with the cell 
line СЕМ that expresses comparable amounts of CD7 antigen as malignant Τ 
cells of most patients. More than 6-logs of СЕМ appeared to be 
eliminated after incubation with 10-e M WTl-ricin A. 
Immunotoxins are only effective after entering the target cell. The 
pattern of internalization of the IT was determined by means cf 12!>i-
WT1. After internalization the CD7 antigen was re-expressed on the cell 
membrane. This enables a long incubation period resulting in an 
increased elimination of malignant Τ cells. Even after 16 hrs the IT was 
still accumulated intracellularly. This pattern of continuous uptake of 
IT was reflected in a gradually increasing cytotoxicity with incubation 
time. Effective bone marrow purging can be carried out without adverse 
effects on progenitor cells with l0-e M WTl-ricin A. At that 
concentration the antibody binding capacity was saturated. 
We showed that the protein synthesis inhibition in malignant Τ 
cells by WTl-ricin A is comparable to the inhibition in Τ cell lines and 
that high amounts of СЕМ cells can be killed. These data suggest that 
cell lines can be used to test the efficacy of IT to malignant Τ cells. 
WTl-ricin A appears to be very potent for the purging of autologous bone 
marrow from patients with Τ cell malignancies. 
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mTRODUCTION 
Autologous bone marrow transplantation (ABUT) is currently being 
investigated as a therapy for patients with acute leukaemia or lymphoma 
who do not have a HLA-matched sibling donor. Residual malignant cells 
contaminating the bone marrow of patients in complete remission, may be 
responsible for the high relapse rate after АВГСГ (Dicke et al, 1984; 
Santos & Kaizer, 1984; Gorin et al, 1986). Effective ex vivo purging of 
the bone marrow, however, may improve the therapeutic efficacy. 
Immunotoxins (IT) are considered to be very useful to eliminate 
selectively leukemic cells from the bone marrow. The efficacy depends on 
several cellular properties such as antigen density and internalization 
capacity, type of target cell, the nature of the toxin, and the 
incubation conditions (Casellas et al, 1985; Uckun et al, 1985; Press 
et al, 1986; Youle et al, 1986; Preijers et al, 1988a, b). Cytotoxicity 
of ricin Α-chain IT can be enhanced considerably by lysosomotropic 
amines such as ammonium chloride or ionophores as monensin and nigericin 
(Casellas et al, 1984). 
Before clinical applications can be instituted, the cytotoxic 
efficacy of the IT to the leukaemic cells of individual patients has to 
be determined to warrant an optimal elimination. In the absence of a 
reliable cloning method for leukaemic Τ cells, the cytotoxic efficacy of 
IT to clonogenic cells is usually tested by means of leukaemic human Τ 
cell lines. Since there is no evidence in literature that the cytotoxic 
efficacy of IT to leukaemic cells can be compared to cell lines, this 
study was performed. The anti-CD7 monoclonal antibody (MoAb) WT1 
(Vodinelich et al, 1983) conjugated to ricin A, appeared to be a very 
potent inhibitor of protein synthesis of human Τ cell lines and offers a 
promising approach for the removal of malignant Τ cells from bone marrow 
in vitro without being harmful to haematopoietic progenitors (Myers et 
al, 1984; Preijers et al, 1988a, b). 
In this report we describe the cytotoxicity of WTl-ricin A to 
leukaemic Τ cells, compared to Τ cell lines, and the optimal conditions 
for incubation based on the absolute amount of internalized MoAb. A 
relation was found between antigen density and the ID50 of WTl-ricin A 
for malignant Τ cells of most patients and appeared comparable to that 
previously observed in cell lines (Preijers et al, 1988a). WTl-ricin A 
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appeared effective for the ex vivo elimination of malignant Τ cells from 
bone marrow of patients without compromising the repopulation capacity 
of the autologous grafted bone marrow. Patients with a low density of 
CD7 on their malignant Τ cells tended to relapse earlier (to be 
published). 
MRTERIALS AND METHODS 
Cell lines and malignant Τ cells 
τ cell acute lymphoblastic leukaemia (T-ALL) lines, strongly varying in 
CD7 expression, were selected: GH1, СЕМ, Jurkat, HSB-2 and HPB-ALL. 
cells were cultured in RPMI 1640 supplemented with 5% heat inactivated 
fetal calf serum (FCS; HyClone Labs, Logan, Utah), 2 mM glutamine, 1 mM 
sodium pyruvate and gentamycm (50 цд/ті) in a humidified incubator 
with 5% C02 in air at 370C. 
Malignant τ cells were obtained from untreated patients with T-ALL 
or lymphoblastic lymphoma (T-LL). T-ALL cells were enriched from bone 
marrow by Ficoll (1.077 g/ml) centrifugation, whereas T-LL cells were 
isolated from lymph node tissue obtained by biopsy. Tissue was gently 
pressed through a 70 цт nylon filter, washed and centrifugated on Ficoll 
(Janssen et al, 1984). The isolated cell population of all patients 
consisted of more than 90% CD7-positive cells, as determined by flow 
cytometry (FCM). The cell suspensions contained comparable numbers of 
malignant cells as was proven by morphologic analysis. The cells were 
suspended in culture medium and used directly, or cryopreserved with 10% 
dimethylsulphoxide (DMSO) according to a computerized freezing programme 
with maintenance of their functional and growth potential (Van de 
Ouweland et al, 1982). 
loffliunotoxin 
The murine anti-human Τ cell MoAb: WT1, anti-CD7 (Tax et al, 1984) was 
purified by means of Staphylococcus aureus protein A coupled to 
Sepharose (Pharmacia). 
Ricin A was kindly provided by Dr F.К. Jansen, Centre de Recherches 
Clin Midy, Montpellier, France. WT1 was conjugated to ricin A by means 
of succinimidyl 3-(2-pyridyldithio) propionate (SPDP; Pharmacia) as 
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described elsewhere (Preijers et al, 1988a). The conjugated MoAb was 
disposed of free antibody and free Α-chain by Sephacryl S200 gel 
filtration. The conjugate was analyzed by SDS-page gel electrophoresis. 
The molar ratio of ricin Α-chain and antibody, determined by 
radioimmunoassay, appeared to vary between l and 1.8. The preservation 
of the antibody binding activity after conjugation was proven by FCM and 
enzyme linked immunosorbent assay (ELISA). 
Antigen density and internalization 
WT1 was labelled with 1Z5lodine (Amersham International, Amersham 
Bucks., UK) using the chloramine Τ method (Hunter, 1973). The 
concentration and specific activity of the ^"'I-labelled MoAb were 
determined by respectively radioimmunoassay and binding assay with 
limiting quantities of labelled antibody. The absolute number of binding 
sites per cell was determined as described previously (Preijers et al, 
1988a). 
The amount of internalized MoAb was determined as described (Tax et 
al, 1987). Briefly, IO6 target cells in RPMI with 1% BSA were incubated 
with various concentrations '"I-MoAb for 1 hr, or with fixed 
concentrations for various times at 37°C or 40C in a final volume of 100 
μΐ. The cells were washed, counted for total radioactivity, and 
incubated with 1 mg/ml pronase for 2 hrs at 40C. Subsequently, the 
cells were washed and radioactivity was counted. The absolute amount of 
internalized MoAb was calculated from the pronase treated cells 
initially incubated at 37°C corrected for the pronase treated cells 
initially incubated at 40C, and the concentration of 12Эі-моАЬ in the 
incubation medium. Binding at 370C was determined by subtraction of the 
internalized radioactivity from the total radioactivity after incubation 
at 37<»C. 
Protein synthesis inhibition by WTl-ricin A 
Cytotoxicity assays were carried out in triplicate in 96-wells U-
bottomed plates (Costar, Cambridge, MS). Cell lines were incubated in 
culture medium and fresh or thawed cryopreserved leukaemic cells in EMEM 
without leucine (Flow Labs, Irvine, Scotland, UK) supplemented with 5% 
FCS, 2 mM glutamine, 1 mM sodium pyruvate and gentamycin (50 цд/ті). 
Each well was filled with 105 cells supplemented with varying 
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concentrations of IT in the absence or the presence of 6 mM NH
e
Cl to a 
final volume of 200 μΐ. Cells were incubated for 24 hrs at 370C in a 
humidified incubator with 5% C02 in air, followed by 24 hrs incubation 
with 0.5 цСі 3H-leucine (TRK510, Amersham). To enable kinetic studies 
cells were incubated for various periods of time with 10-β M WTl-ricin A 
followed by a labelling for 1 hr with l цСі 3H-leucine. Cells were 
harvested and radioactivity was counted. The cytotoxicity was expressed 
as percentage inhibition of 3H-leucine incorporation of untreated cells 
corrected for the background value determined in the presence of 1 mM 
cycloheximide. No differences were observed between fresh and 
cryopreserved cells (data not shown). 
Clonogenic assay 
The clonogenicity of СЕМ cells was determined with the double agar layer 
cloning assay (Casellas et al, 1985). Cells in exponential phase of 
growth were incubated for 24 hrs in RPMI 1640 plus 10% FCS with 
concentrations of WTl-ricin A varying between 10-B and ΙΟ-1" M in the 
absence or the presence of 6 mM NH^Cl. The cells were washed and 
resuspended in cloning medium consisting of RPMI supplemented with 1 mM 
^-ketoglutarate (Sigma, St. Louis, USA), 1 mM sodium oxaloacetate 
(Sigma), 5% FCS, and 10% heat-inactivated horse serum. Numbers of cells, 
varying between 10p and 10 e, were plated in 2.5 ml cloning medium with 
0.3% agarose (type VII, Sigma) upon a bottom layer of 2.5 ml of the same 
medium in 60 mm culture dishes (Costar). The cells were incubated at 
370C for 20 days and colonies were scored. The cloning frequency of IT 
treated cells was determined by means of the plating efficiency of 
untreated cells that were seeded from 1 to 100 cells/well. Absolute 
numbers of surviving cells were calculated from the number of colonies, 
the dilution of cells and the cloning frequency. 
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RESULTS 
Protein synthesis inhibition of Τ cell lines 
Cytotoxic potency of WTl-ricin A in the presence of 6 mM ammonium 
chloride was tested on Τ cell lines: GHl, СЕМ, Jurkat, HSB-2 and HPB-ALL 
and based on protein synthesis inhibition. Ammonium chloride as such did 
not affect protein synthesis. The antigen density of the cell lines, 
which varied from 20 kD (HPB-ALL) to 175 kD (GHl), was directly 
proportional to the cytotoxicity of the IT as determined by linear 
regression analysis (p<0.01,· Fig 1A). 
200 
DINSITY OF CD7 (MDLÍCULES PER CELL X 10 
Fig. 1. Efficacy of WTl-ricin A in relation to antigen density of CD7 on 
Τ cell lines: GHl ( · ), Jurkat (Π), СЕМ ( • ), HSB-2 (О) , and 
HPB-ALL ( • ) (A), and on malignant Τ cells of 14 patients with 
T-ALL or T-LL (B). Results are expressed as ID50 of IT in the 
presence of 6 niM NH„Cl in relation to the maximum binding of 
1Z5I-WT1 per cell. MoAb binding and ID50 were both the mean of 
triplicates of three independent experiments. Standard deviation 
was less than 10%. Standard line was obtained with linear 
regression analysis. 
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Protein synthesis inhibition of malignant τ cells 
Protein synthesis inhibition of WTl-ricin A in the presence of 6 mM 
NHiCl in malignant Τ cells of patients with T-ALL or T-LL was calculated 
from the dose response curves and expressed as ID50 (Table I). Malignant 
cells from non-T origin from patients with C-ALL or B-ALL were used as 
controls. They showed no CD7 expression and hardly any inhibition of 
protein synthesis (ID50 >10-7 M). Malignant τ cells were variably 
sensitive to WTl-ricin A. As shown in Table I, the cells from different 
patients varied considerably in antigen density. Comparison of the ID50-
values and the number of CD7 binding sites per cell by linear regression 
Table I. Experimental data of patients. 
Patient 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
Diagnosis 
T-ALL 
T-ALL 
T-LL 
T-ALL 
T-LL 
T-ALL 
T-LL 
T-ALL 
T-LL 
T-LL 
T-ALL 
T-ALL 
T-ALL 
T-LL 
Ag-density1 
(Mol./cellxlO-3) 
21 
45 
39 
85 
74 
250 
35 
87 
30 
5 
29 
118 
65 
48 
ID502 
(M) 
10-9 
4ХІ0-10 
3xl0-10 
10-11 
1.5X10-11 
10-11 
1.5ХІ0-10 
7x10-17-
10-10 
3xl0-e 
2ХІ0-10 
ЗХІ0-11 
4ХІ0-11 
6ХІ0-11 
'Antigen density of CD7 on the malignant cells of patients 
with T-ALL or T-LL as measured by 125I-WT1 expressed in 
average number of molecules per cell. 
2ID50 of WTl-ricin A in the presence of 6 mM NH
a
Cl. 
Data are the results of at least three experiments. 
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analysis showed a good correlation for most patients (p<0.001; Fig IB). 
The regression line was almost similar to the line found for τ cell 
lines. Only the data of patient 6 with the highest antigen density on 
his malignant cells diverged from the data of the other patients. 
Statistical analysis of the 95% confidence limits of the antigen density 
and the ID50 in cell lines and in malignant Τ cells of patients showed a 
significant relation, which suggests that the cytotoxicity of WTl-ricin 
A to cell lines and leukaemic cells is comparable. 
Cell kill by WTl-ricin A 
The protein synthesis inhibition by WTl-ricin A in malignant τ cells is 
comparable to that observed in Τ cell lines. Presently no reproducible 
and satisfactory clonogenic assay of malignant Τ cells is available to 
determine the exact amount of cells eliminated by an IT. The killing 
potency of the IT treatment to malignant Τ cells is approached by a 
cloning assay with the human Τ cell line: СЕМ, that expresses CD7 
antigen in comparable amounts as the malignant Τ cells of most patients. 
In this assay an average cloning frequency of untreated cells of 90% in 
the absence and 65% in the presence of NH4C1 with an intra-assay 
standard deviation of less than 10% was achieved. Cells were exposed 
to various concentrations of WTl-ricin A with or without NH^Cl and 
cultured in various cell concentrations to determine the number of 
residual clonogenic cells after treatment (Fig 2). WTl-ricin A 
(10-β M) in the absence of NH^Cl reduced almost 99% (2-logs) of the 
clonogenic cells, but in the presence of 6 mM NH4CI ΙΟ-9 M IT reduced 
the number of clonogenic cells with 6-logs (0.0001% residual cells, 
n=3). A higher IT concentration (l0-e M) resulted even in a more 
substantial kill exceeding 6-logs. The exact degree of elimination at 
that concentration could not be determined due to the seeding limit (I0ft 
cells) of the assay. These results suggest that 10-e M WTl-ricin A 
with 6 mM NHiCl may be extremely effective for the elimination of 
malignant clonogenic Τ cells from bone marrow. 
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10 " 10 " 10 " 10 
CONCENTRATION OF WTl-RICIN A (И) 
Fig. 2. Cell survival after treatment of СЕМ with WTl-ricin A with or 
without МН
Л
С1 assessed by clonogenic assay, cells were incubated 
with various concentrations WTl-ricin A in the absence ( · ) or 
the presence (О) of 6 mM NH«C1. Number of surviving cells was 
calculated from the cloning frequency of untreated cells. Each 
point represents the mean of triplicate cultures from three 
experiments. Standard deviations were less than 10%. 
Internalization of WT1 
Cytotoxicity of IT depends on the amount internalized. In order to 
decrease the possibility of haematopoietic stem cell reduction and to 
optimalize the elimination of malignant cells from the bone marrow, we 
studied the influence of concentration and incubation time on the 
internalization of the IT. To determine the influence of the 
concentration on the amount of cell bound and internalized MoAb СЕМ 
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Fig. 3. Influence of concentration and incubation time on the binding at 
at 4oC ( · ) and 370C ( О ) , and internalization ( Δ ) of WTl 
into СЕМ. СЕМ cells were incubated for 1 hr with 125І-іаЬе11еа 
WTl in various concentrations (A), or in fixed concentration (B, 
2 цд/ті) for various periods at 40C and 370C. 
cells were incubated with various concentrations of 125Іоаіпе-1аЬе11еа 
WTl at 40C and 3 7 ^ for 1 hr, followed by a stripping procedure to 
remove surface bound antibody (Fig ЗА). Both incubations at 40C and at 
370C with a MoAb concentration higher than 1 ug/ml (6.7xlO-9M) resulted 
in a saturation of the cell binding potency. When СЕМ was incubated at 
37°C, a slightly lower antigen expression was found. The amount of 
internalized MoAb was directly proportional to the amount of cell bound 
MoAb resulting in a percentage of internalization (76%) which remained 
equal over a wide range of concentrations. 
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The kinetics of WTl internalization was determined with a saturating 
concentration of :ia5I-WTl (2 цд/ті; Fig 3B). The amount of MoAb bound to 
СЕМ at 40C was not significantly changed in time. The amount oí surface 
bound MoAb at 370C decreased in time, but CD7 expression never 
disappeared completely. WTl was rapidly internalized during the first 4 
hours. Thereafter the internalization slowed down, but WTl continued to 
accumulate intracellularly even after 16 hrs. The number of internalized 
WTl molecules surpassed the number of cell bound WTl within 1.5 hr 
suggesting antigen reappearance after internalization. 
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Fig. 4. Cytotoxicity kinetics of WTl-ricin A in the presence of ammonium 
chloride to Τ cell lines. Cells were incubated with 10-e M WTl-
ricin A in the presence of 6 mM NH.»C1 for various periods of 
time followed by an 1 hr uptake of 3H-leucine. Inhibition of 
protein synthesis is expressed as percentage 3H-leucine 
incorporation of untreated controls. Each point represents the 
mean of triplicate incubation from three experiments. Standard 
deviations were less than 10%. (·) GH1; (o) Jurkat; (•) СЕМ; 
(O) HSB-2; (•) HPB-ALL. 
100 
The internalization kinetics determined by this assay was limited to 
16 hrs since after that time a pronounced cell mortality occurred due to 
irradiation. Incubation for 24 hrs with a nonsense 1Z5I-MoAb resulted 
in a 80% cell loss as determined by trypane blue exclusion, whereas 
unlabelled WT1 did not influence the viability. 
With a nonsaturating concentration (0.2 ug/ml WT1) cells required a 
longer period to attain the same amount of internalized antibody as 
cells incubated with a saturing concentration (data not shown). 
Kinetics of protein synthesis inhibition 
In order to study the influence of the incubation time directly on the 
cytotoxicity of WTl-ricin A the kinetics of protein synthesis inhibition 
was determined. The relation between the cytotoxic efficacy of WTl-ricin 
A and the antigen density was also observed during kinetic studies with 
l0-e M (1,5 цд/ті) IT in incubation periods up to 24 hrs (Fig 4). High 
antigen density on the target cells resulted in a fast inhibition of the 
protein synthesis. Inhibition of 50% of the ""H-leucine incorporation in 
GHl was achieved within l hr in contrast to 14 hrs for HPB-ALL. The 
inhibition of protein synthesis in time was comparable to the pattern of 
a continuous uptake of IT (Fig 3). 
DISCUSSICM 
Our and other studies have shown that IT offer a promising approach for 
the elimination of leukaemic cells (Myers et al, 1984; Casellas et al, 
1985; Preijers et al, 1988a). Most studies have been carried out on 
cell lines only, though there may be differences in sensitivity of 
malignant cells for the IT in comparison to cell lines. Therefore we 
studied the cytotoxic efficacy of WTl-ricin A on malignant Τ 
cells collected from patients before initiation of chemotherapy and 
compared the data with the cytotoxicity to Τ cell lines. As recently 
described (Myers et al, 1984; Preijers et al, 1988a), WTl-ricin A in the 
presence of ammonium chloride inhibits the protein synthesis of cell 
lines very effectively depending on antigen expression and exposition 
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duration of the target cells. We found that the inhibition by WTl-ricin 
A in malignant Τ cells was also related to the antigen density, 
comparable with τ cell lines (Preijers et al, 1988a). This implicates, 
as also suggested by Laurent et al (1986), that the sensitivity of the 
malignant Τ cells for the IT differs from one patient to another. The 
measurement of antigen density on the malignant cells of each patient 
may predict the cytotoxicity of the IT. The present data suggest that 
cell lines can be used as a model to screen initially the suitability 
and optimal killing conditions of the IT. Before clinical application 
cytotoxicity to the malignant Τ cells of the individual patients has to 
be determined to select patients for bone marrow purging. 
Many investigators have tried to culture malignant Τ cells to show 
the absolute amount of cell kill (Smith et al, 1986; Georgoulias et al, 
1986). At present there is no satisfactory cloning method for leukaemic 
τ cells. To approach the clinical situation a clonogenic assay for Τ 
cell lines was used. Formally this assay will not be an evidence for 
leukaemic cell kill. However, data from other clonogenic assays, 
carried out in liquid culture on all cell lines used in this study, 
showed that the relation between antigen density and killing capacity of 
WTl-ricin A was similar to that found with protein synthesis inhibition 
(to be published). 
In the clonogenic assay decribed in this paper an elimination of 
more than 6-logs of СЕМ cells was observed with WTl-ricin A in the 
presence of 6 mM ammonium chloride. These results are comparable to 
data of Casellas et al (1985) concerning the cytotoxicity of TlOl-ricin 
A to СЕМ. Myers et al (1984) found that after a 3 hrs treatment of GH1 
with WTl-ricin A lese than 0.1% of the cells survived. These data 
suggest that ricin A IT are very potent for the elimination of malignant 
Τ cells and provide an alternative superior to other reported cytotoxic 
agents which possess either lower cytotoxicity (complement-mediated 
kill: Bast et al, 1983; De Fabritiis et al, 1985; Favrot et al, 1986; 
Preijers et al, 1988c) or which are less specific (Rowley et al, 1987). 
In most experiments cell lines and malignant Τ cells were incubated 
with IT for 24 hrs. For practical reasons a reduction of the incubation 
time prior to ABUT is advantageous. The cytotoxicity of IT, however, 
depends on the internalization capacity of the antigen. Therefore we 
studied the kinetics of internalization and it appeared that WTl was 
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rapidly internalized, within 1.5 hr the amount of internalized WT1 
exceeded the amount of cell bound WTl. This implicates a continuous 
synthesis or reappearance of antigen on the cell surface. In contrast 
to data of Myers et al (1984), we found that CD7 did not disappear 
completely from the cell membrane within 16 hrs explaining the 
continuous uptaXe of WTl. The amount of internalized WTl was strongly 
related to the amount of cell bound antibody within a wide range of 
concentrations. This may be important for the use of WTl-ricin A in a 
cocktail of IT in which each IT has to be diluted to achieve an optimal 
concentration of ricin Α-chain that will cause no nonspecific 
cytotoxicity. 
The continuous internalization of WTl was reflected in the kinetics 
of cytotoxicity of WTl-ricin A. The cells were incubated with a 
saturating IT concentration of 1.5 цд/ті (10-β M). After the initially 
rapid inhibition within 4 hrs, protein synthesis continued to decrease. 
These data justify a long incubation time for an optimal elimination of 
malignant Τ cells from bone marrow intended for reinfusion. By the 
continuous internalization of IT also cells with a low density of CD7 
have a higher chance to be killed by surpassing the threshold of the 
amount of internalized ricin A necessary for its deleterious action 
(Casellas et al, 1982). 
As previously observed, bone marrow precursor cells (CFU-GM and BFU-
E) are not detectably affected during the long term incubation period 
(Preijers et al, 1988b). At present 11 patients with τ lymphoblastic 
malignancies have received an autotransplant after incubation of the 
marrow with 10-β M WTl-ricin A in the presence of 6 mM NH
a
cl for 16 hrs. 
Two patients who had the lowest antigen (CD7) density on their malignant 
cells relapsed suggesting an incomplete elimination of malignant Τ cells 
from their bone marrow. Two patients died by transplantation related 
complications. Seven patients are alive and well (median survival 21 
months). Extension of autotransplants and a longer follow-up of the 
patients are required to confirm whether in this much more complicated 
situation still a relation exists between antigen density and cell kill 
with relapse-free survival. Clinical details from the ΆΒΜΓ results will 
be published elsewhere. 
From our studies we conclude: Τ cell lines seem to be useful as 
model for testing the potency of ricin Α-chain IT towards malignant Τ 
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cells and to study more basically the way of action. WTl-ricin A is a 
very potent IT for the purging of bone marrow of patients suffering from 
Τ cell malignancies because this IT is highly effective at the 
saturating concentration of 10-β M. The long incubation period with this 
IT is justified due to re-expression of the CD7 antigen on the cell 
membrane. No adverse effects on haematopoietic progenitor cells occur 
under these conditions. 
ACKNOWLEDGEMENT 
This work was supported in part by a grant of the Ahk van Vlissingen 
Foundation. We are indebted to Dr P. Casellas and X. Canat for 
assistance with the development of the clonogenic assay; to Dr W. Tax 
for provision of WT1; to Dr F.К. Jansen for provision of purified ricin 
Α-chain; to Prof Dr G. de Gast, Dr E. Bast and Dr E. van Leeuwen for 
their support in ABMT. 
104 
RKFKWjKCES 
Bast, R.C. Jr., Ritz, J., Lipton, J.M., Feeney, M., Sallan, S.C., 
Nathan, D.G. & Schlossman, S.F. (1983) Elimination of leukemic cells 
from bone marrow using monoclonal antibody and complement. Cancer 
Research, 43, 1389-1394. 
Casellas, P., Brown, J.P., Gros, О., Gros, P., HellstrOm, I., Jansen, 
F.К., Poncelet, P., Roncucci, R., Vidal, H. ь HellstrOm, Κ.E. (1982) 
Human melanoma cells can be killed in vitro by an immunotoxin specific 
for melanoma-associated antigen p97. international Journal of Cancer, 
30, 437-443. 
Casellas, P., Bourne, B.J.P., Gros, P. ь Jansen, F.К. (1984) Kinetics 
of cytotoxicity induced by immunotoxins: Enhancement by lysosomotropic 
amines and carboxylic lonophores. Journal of Biological Chemistry, 
259, 9359-9364. 
Casellas, P., Canat, X., Fauser, A.A., Gros, 0., Laurent, G., Poncelet, 
P. & Jansen, F.К. (1985) Optimal elimination of leukemic Τ cells from 
bone marrow with Tioi-ncin Α-chain immunotoxin. Blood, 65, 289-297. 
Dicke, К.A., Jagannath, S., Spitzer, G., Poynton, с . Zander, Α., 
Vellekoop, L., Reading, C.L. , Jelm, U.W. & Tindle, S. (1984) The role 
of autologous bone marrow transplantation in various malignancies. 
Seminars in Hematology, 21, 109-122. 
De Fabritiis, P., Bregni, Μ., Lipton, J., Greenberger, J., Nadler, L., 
Rothstein, L., Korbling, M., Ritz, J. & Bast, R.C. Jr. (1985) 
Elimination of clonogenic Burkitt's lymphoma cells from bone marrow 
using 4-hydroperoxycyclophosphamide (4-HC) in combination with 
monoclonal antibodies and complement. Blood, 65, 1064-1070. 
Favrot, M.C., Philip, I., Philip, T., Pinkerton, R., Lebacq, A.M., 
Forster, К., Adeline, P. & Doré, J.F. (1986) Bone marrow purging 
procedure in Burkitt lymphoma with monoclonal antibodies and 
complement: quantification by a liquid cell culture monitoring system. 
British Journal of Haematology, 64, 161-168. 
Georgoulias, V., Triebel, F., Kosmatopoulos, С , Allouche, Μ., Gluckman, 
J.C., Mathe, G. s- Jasmin, С (1986) T-cell colony formation in 
patients with T-cell malignancies: growth factor requirements for in 
vitro proliferation of peripheral blood T-cell colony-forming cells. 
Leukemia Research, 10, 419-427. 
105 
Gönn, N.C., Hervé, P., Aegerter, P., Goldstone, Α., Linch, D., 
Maraninchi, D., Burnett, Α., Heibig, W., Meloni, G., Verdonck, L.F., 
De Witte, T., Rizoli, V., Carella, Α., Parlier, Y., Auvert, В. s. 
Goldman, J. (1986) Autologous bone marrow transplantation for acute 
leukaemia in remission. British Journal of Haematology, 64, 385-395. 
Hunter, W.H. (1973) Radioimmunoassay. In Handbook of Experimental 
Immunology (ed. by D.M. Weir) pp. 17.1-17.36. Blackwell Scientific 
Pubi., Oxford. 
Janssen, J.T.P., De Pauw, в.E., Smeulders, J.B.J.M., Wessels, J.M.C, ь 
Haanen, С. (1984) Lymphocyte isolation from human spleen by counter 
flow centrifugation employing two different flow chambers on line. 
Journal of Immunological Methods, 70, 23-30. 
Laurent, G., Kuhlein, Ε., Casellas, P., Canat, X., Carayon, P., 
Poncelet, P., Correli, S., Rigai, F. s. Jansen, F.К. (1986) 
Determination of sensitivity of fresh leukemia cells to immunotoxins. 
Cancer Research, 46, 2289-2294. 
Myers, CD., Thorpe, P.E., Ross, W.C.J., Cumber, A.J., Katz, F.E., Tax, 
W. & Greaves, M.F. (1984) An immunotoxin with therapeutical 
potential in Τ cell leukemia: WTl-ricin A. Blood, 63, 1178-1185. 
Van de Ouweland, F., De Witte, T., Geerdink, P. & Haanen, С. (1982) 
Enrichment and cryopreservation of bone marrow progenitor cells for 
autologous reinfusion. Cryobiology, 19, 292-298. 
Preijers, F.W.M.B., Tax, W.J.M., De Witte, T.J.M., Janssen, Α., Van der 
Heijden, Η., Vidal, Η., Wessels, J.M.C, i Capel, P.J.A. (1988a) 
Relationship between internalization and cytotoxicity of ricin A-chain 
immunotoxins. British Journal of Haematology, 70, 289-294. 
Preijers, F.W.M.B., Tax, W.J.M., Wessels, J.M.C., Capel, P.J.A., De 
Witte, Т. ь Haanen, С. (1988b) Different susceptibilities of normal Τ 
cells and Τ cell lines to immunotoxins. Scandinavian Journal of 
Immunology, 27, 533-540. 
Preijers, F.W.M.B., De Witte, T., Rijke-Schilder, G.P.M., Tax, W.J.M., 
Wessels, J.M.c., Haanen, С. ь Capel, P.J.A. (1988c) Human τ 
lymphocyte differentiation antigens as target for immunotoxins or 
complement-mediated cytotoxicity. Scandinavian Journal of Immunology, 
28, 185-194. 
Press, O.W., Vitetta, E.S., Farr, A.G., Hansen, J.А. ь Martin, P.J. 
(1986) Evaluation of ricin A-chain immunotoxins directed against human 
106 
Τ cells. Cellular Immunology, 102, 10-20. 
Rowley, S.D., Zuehlsdorf, M., Braine, H.G., Colvin, O.M., Davis, J., 
Jones, R.J., Sarai, R., Sensenbrenner, L.L., Yeager, A. & Santos, G.W. 
(1987) CFU-GM content of bone marow graft correlates with time to 
hematologic reconstitution following autologous bone marrow 
transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. 
Blood, 70, 271-275. 
Santos, G.W. ь Kaizer, H. (1984) In vitro chemotherapy as a prelude to 
autologous marrow transplantation in hematological malignancy. In 
Minimal residual disease in acute leukemia (ed. by B. LOwenberg and 
A. Hagenbeek) pp 165-181. Martinus Nijhoff, Boston. 
Smith, S.D., Morgan, R., Link, M.P., McFall, P. ь Hecht, F. (1986) 
Cytogenetic and immunophenotypic analysis of cell lines established 
from patients with τ cell leukemia/lymphoma. Blood, 67, 650-656. 
Tax, W.J.M., Tidman, N., Janossy, G., Trejdosiewicz, L., Willems, R., 
Leeuwenberg, J., De Witte, T.J.M., capel, P.J.A. s, Koene, R.A.P. 
(1984) Monoclonal antibody (WTl) directed against a Τ cell surface 
glycoprotein: characteristics and immunosuppressive activity. Clinical 
and Experimental Immunology, 55, 427-436. 
Tax, W.J.M., Van der Heijden, H.M.W., Capel, P.J.Α. ь Koene, R.A.P. 
(1987) Internalization (but no recycling) of Τ cell receptor, T3 
antigen, and other Τ cell antigens. Transplantation Proceedings, 19, 
273-276. 
Uckun, F.M., Ramakrishnan, S. & Houston, L.L. (1985) Immunotoxin-
mediated elimination of clonogenic tumor cells in the presence of 
human bone marrow. Journal of Immunology, 134, 2010-2016. 
Vodinelich, L, Tax, W., Bai, Y., Pegram, S., Capel, P. s, Greaves, M. 
(1983) A monoclonal antibody (WTl) for detecting leukemias of T-cell 
precursors (T-ALL). Blood, 62, 1108-1113. 
Youle, R.J., Uckun, F.M., Vallera, D.A. & Colombatti, M. (1986) 
Immunotoxins show rapid entry of diphteria toxin but not ricin via the 
Τ3 antigen. Journal of Immunology, 136, 93-98. 
107 

C H Z V F T E R β 
AUTOLOGOUS ΤΗΑΝΒΡΙΑΝΊΜΊΟΝ OF ВШЕ NARROW PURGED IN VITRO WITO 
ANTI-CD7-(WT1) RICIN A INMUNOTQXIN Ш Τ CELL 
LYNPHQBIASTIC LEUKQÏIA AND LYMPHOMA. 
F.W.M.B. Preijers, T. de Witte, J.M.C. Wessels, G.C. de Gast", E. 
van Leeuwen**, P.J.A. Capel*** and С. Haanen. 
From Department of Hematology, University Hospital Nijmegen; 
'Department of Hematology, University Hospital Utrecht; 
•"Children's Hospital "Emma Kinderziekenhuis", Amsterdam; and 
"""Department of Experimental Immunology, State University 
Utrecht, The Netherlands. 
Submitted for publication, 1988. 
109 
ABSTRACT 
Seven patients with high risk acute τ cell lymphoblastic leukemia (T-
ALL) and five with Τ cell lymphoma (T-LL) were treated with autologous 
bone marrow transplantation (ABMT) after in vitro purging of their bone 
marrow with WTl (CD7)-ricin Α-chain immunotoxin. CD7 expression on the 
tumor cells showed large variations between the individual patients and 
was highly related to the specific cytotoxicity of WTl-ricin A. 
Incubation of bone marrow with up to 10-β M WTl-ricin A in the presence 
of 6 mM NH4CI did not compromise the growth potential of the 
hematopoietic progenitors CFU-GM, CFU-GEMM and BFU-E. Hematologic 
engraftment (>109 leukocytes/1) occurred within a normal time period 
(median: 15.5 days). Six patients are alive and in complete remission 
(CR) at 44+, 40+, 36+, 22+, 7+ and 3+ months after ABMT. Four patients 
relapsed within 6 months after ABMT. Two of them had the lowest CD7 
expression on their tumor cells, the other two were transplanted in CR2 
and CR3. Two patients died from transplantation related infections. 
The immunologic reconstitution was delayed, although the numbers of 
Τ cells reached normal levels within l month. The number of CD7* cells 
remained low up to one year after transplantation. The T4/T8-ratio was 
decreased for at least 6 months. The Τ cell response to mitogens 
recovered to normal levels after one year. This study shows that ABMT 
with WTl-ricin A purged bone marrow in high risk Τ cell malignancies 
results in a complete hematopoietic and a delayed immunologic 
reconstitution. The actuarial relapse free survival is 56% at 3 years. 
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ПГПЮШСТІСМ 
Autologous bone marrow transplantation (АВМГ) is increasingly applied as 
alternative treatment for patients with acute τ cell lymphoblastic 
leukemia (T-ALL) or lymphoma (T-LL) who lack a HLA-compatible donor 
(1-6). Bone marrow, even when aspirated during complete remission, is 
probably contaminated with residual malignant Τ cells, and these may be 
responsible for relapse after ABMT. Various techniques have been 
developed to eliminate in vitro the malignant cells from the graft (7-
14). Purging of the bone marrow with ricin Α-chain immunotoxins (ITs) 
specifically directed against the malignant τ cells appeared to be a 
promising approach to improve the therapeutical efficacy of АВШ" (7-10). 
Recently we showed that CD7 is a suitable antigen as target for ITs 
(7,15) since CD7 is expressed in most τ cell malignancies. The IT WTl-
ricin A (anti-CD7) appeared to eliminate very effectively malignant Τ 
cells from the bone marrow, in part due to continuous internalization of 
the antigen-IT complex by the cells, provided that the CD7 density on 
the cell surface was high. We demonstrated that WTl-ricin A in the 
presence of 6 mM ammonium chloride induces more than 6-logs kill of the 
malignant Τ cell line 'СЕМ' (15). 
In this paper we report clinical and experimental data of ABMT, 
using bone marrow purged in vitro with WTl-ricin A, in 12 patients 
suffering from bad risk T-ALL and T-LL in complete remission. 
MATERIALS. METHODS AMD PATIENTS 
Inmunotoxin 
Ricin A was kindly provided by Dr F.К. Jansen (Centre de Recherches Clin 
Midy, Montpellier, France). The murine anti-human Τ cell MoAb: WTl, 
anti-CD7 (kindly provided by Dr W.Tax; 16) was conjugated to ricin A by 
means of succinimidyl 3-(2-pyridyldithio) propionate (SPDP; Pharmacia) 
as described previously (7). 
Antigen denstity 
WTl was labelled with 125Iodine (Amersham International, Amersham, 
Bucks., UK) using the chloramine Τ method (37). The concentration and 
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specific activity of the 125l-labelled MoAb were determined by 
respectively radioimmunoassay and binding assay with limiting quantities 
of labelled antibody. The absolute number of binding sites per cell was 
determined as described previously (7). 
Cytotoxicity of WTl-ricin A 
Fresh or thawed cryopreserved leukemic cells were incubated in EMEM 
without leucine (Flow Labs, Irvine, Scotland, UK) supplemented with 5% 
fetal calf serum (FCS), 2 mM glutamine, 1 mM sodium pyruvate and 
gentamycin (50 цд/ті). Each well of U-bottomed plates (Costar, 
Cambridge, Mass., USA) was filled with 10 5 cells supplemented with 
varying concentrations of IT in the absence or presence of 6 mM Ш
Л
С 1 to 
a final volume of 200 μΐ. Cells were incubated for 24 hrs at 370C in 
a humidified incubator with 5% C02 in air, followed by 24 hrs incubation 
with 0.5 цСі 3H-leucine (TRK510, Amersham). Cells were harvested and 
radioactivity was counted. The cytotoxicity was expressed as percentage 
inhibition of 3H-leucine incorporation of untreated cells corrected for 
the background value determined in the presence of l mM cycloheximide. 
Cytotoxicity to bone marrow progenitor cells 
Bone marrow was aspirated from patients undergoing cardiac surgery 
after informed consent was obtained and anticoagulated with acid citrate 
dextrose (ACD). Erythrocytes and mature granulocytes were removed by 
gradient centri fugation on Ficoll (1.077 g/ml). cells (l06/ml) were 
incubated with ITs (10-e M) with or without 6 mM ammonium chloride for 
24 hrs. Cells were washed and the decrease of bone marrow progenitors 
was determined in clonogenic assays of granulocyte/macrophage and 
granulocyte/erythrocyte/macrophage/megakaryocyte colony-forming cells 
(CFU-GM and CFU-GEMM respectively), and erythroid burst-forming cells 
(BFU-E) as described previously (18). · 
PATIEMTS 
АВМГ was performed in 12 patients with bad risk Τ cell malignancies: 7 
T-ALL and 5 T-LL. Before ΑΒΜΓ eight patients were in CRI, one in CR2 and 
three in CR3 (Table l). None of these patients had an HLA-identical 
sibling donor. The mean age was 21 years (range 10-35 years). Data of 
phenotype of the malignant Τ cells and clinical status of the individual 
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Table l. Clinical data of patients before ΑΒΜΓ. 
Pat. 
NO. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
Age/ 
sex 
27/M 
17/M 
35/M 
24/M 
11/M 
22/M 
10/F 
26/F 
15/M 
17/M 
31/M 
28/M 
Initial 
Diagnosis/ 
Stage 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-ALL 
T-LL, 
TLL, 
T-LL, 
T-LL, 
T-LL, 
ЗА 
4A 
4A 
4A 
ЗА 
Data At Diagnos 
WBC 
10V1 
30 
56 
204 
93 
29 
33 
333 
9 
165 
3 
4 
6 
LDH 
U/l 
330 
1487 
9700 
305 
620 
1483 
2238 
201 
4000 
193 
292 
410 
Hep. 
+ 
-
+ 
+ 
+ 
-
+ 
-
+ 
— 
-
is 
Spi. 
+ / -
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
-
+ 
Status 
Before 
ΆΒΜΓ 
CRI 
CRI 
CRI 
CRI 
CNS 
CR2 
CNS 
CRI 
CR3 
CNS 
CRI 
CR3 
CR3 
CNS 
CRI 
CRI 
CNS 
Ph 
Of M 
enotype 
alignant 
cells 
CDl, 
CD4, 
CD7 
CDl, 
CD7 
CD2, 
CD7 
CD2, 
CD8 
CDl, 
CD8 
CD7 
CD7 
CD7 
CD7 
CD2, 
CD2, CD3, 
CD5, CD7 
CD7 
CD4, CD5, 
CD5, CD7, 
CD5, CD7, 
CD5, CD7 
ABMT, autologous bone marrow transplantation; CNS, previous central 
nervous system localization; CR, complete remission followed by 
remission phase; Hep, hepatomegaly; LDH, lactic dehydrogenase in 
Units/1; Spi. splenomegaly; T-ALL, acute T-cell lymphoblastic leukemia; 
T-LL, T-cell lymphoblastic lymphoma followed by staging; WBC, white 
blood cell counts. 
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patients at time of diagnosis and before ΑΒΜΓ are given in Table 1. 
Antigen density and cytotoxicity of WTl-ricin A to the malignant cells 
was determined prior to the marrow harvest. 
Bone marrow processing 
Bone marrow was aspirated from the posterior iliac crests under general 
anesthesia and anticoagulated with héparine. Hematopoietic progenitor 
cells were enriched by density floatation separation in Percoli 
gradients (17). The low density fraction (d<1.070 g/ml) of the 
separated bone marrow was incubated with l0-e M WTl-ricin A in the 
presence of 6 mM ammonium chloride in RPMI 1640 supplemented with 5% 
FCS, 2 mM glutamine and 50 ug/ml gentamycin at 370C for 16 hrs. After 
incubation cells were washed, cryopreserved and stored until the day of 
reinfusion (designated day 0) (19). Before reinfusion the recovery of 
hematopoietic progenitors CFU-GM and BFU-E before and after IT 
treatment and after cryopreservation was determined (18) to check the 
procedure. Before and after all steps cell recovery and morphology were 
assessed in each fraction. 
Transplantation procedure 
Patients were conditioned with cyclophosphamide (CY) 60 mg/kg under 
protection of 12 mg/kg 2-mercaptopurinethanesulfonate (Mesna) to prevent 
hemorrhagic cystitis on days -6 and -5 and total body irradiation (TBI) 
with a total dose of 800 cGy given in a single fraction or HD-melfalan 
180 mg/mz (patient 5) on day -1. All patients received central nervous 
system prophylaxis with intrathecally methotrexate. On day 0 purged bone 
marrow was thawed rapidly and reinfused immediately. Daily blood counts 
were performed during hypoplasia to define the day of engraftment 
(leukocyte count >lxl09/l). Platelet levels were maintained above 
ZOxlO9/! with irradiated (20 Gy) platelet transfusions. 
Follow up of Τ cell recovery 
Heparinized venous blood and bone marrow aspirates (sternum) were 
obtained from every patient 1, 3, 6 and 12 months posttransplantation. 
Hematologic reconstitution and cell numbers were determined in blood 
count analysis and morphology of blood and bone marrow smears. 
The reconstitution of lymphocyte subpopulations was determined by 
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flow cytometry of the lymphocyte scatter area and indirect immuno­
fluorescence of bound monoclonal antibodies (MoAbs). The following anti-
T cell MoAbs were used: WT32 (CD3; 20), WT1 (CD7; 16) and WT82 (CD8; 20) 
provided by Dr W. Tax; OKT6 (CD1; 21), 0KT4 (CD4; 21), OKT1 (CD5; 21) 
from ORTHO Diagnostic Systems Ine (Raritan, NJ). Additionally were used: 
0KB2, identifying B-cells pre-B cells and granulocytes (22), OKB7 
(identifying В cells expressing the 175 kD antigen; 22); OKMl (CDU; 23) 
and 0KM5 (recognizing monocytes and platelets expressing the 88 kD 
antigen; 24). After the initial incubation with the concerning MoAbs the 
cells were incubated with FlTC-labelled Goat-anti-mouse-IgG fiab'tz-
fragment (GAM-FITC; American Qualex International inc., La Mirada, 
California). 
The functional reconstitution of the Τ lymphocytes was determined in 
stimulation assays carried out in 96-wells U-bottom plates. Each well 
was filled with 10 ь cells in culture medium in the absence or the 
presence of 40 цд/ті phytohaemagglutinin (PHA) or 15 pg/ml concanavalin 
A (Con A) to a final volume of 200 μΐ and incubated at 370C in a 
humidified atmosphere with 5% C02 in air for 48 hrs, followed by a 
labelling with 0.5 цСі 3H-thymidine (TRK 61, Amersham) for 24 hrs. 
Thereafter cells were harvested and radioactivity was counted. The PHA 
or Con A stimulation of lymphocytes of the patients was expressed as 
percentage 3H-thymidine incorporation by PHA or Con A stimulated 
lymphocytes of normal individuals, all corrected for background 
incorporation of unstimulated cells. 
Statistical analysis 
Differences in leukocyte number and hematopoietic progenitors before and 
after IT treatment were statistically analyzed by the matched-pair t-
test. 
To study the adverse effect of IT to the bone marrow the 
hematopoietic recovery was examined by the Kaplan-Meier estimate of 
probability (25). The day of engraftment was defined by the day after 
reinfusion with a leukocyte count of >1.0xl0Vl and rising counts 
thereafter. After АВМГ patients with no evidence of relapse were 
classified as being in complete remission. The overall survival and 
the probability of relapse posttransplant were evaluated by the Kaplan-
Meier method. 
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Table 2. In vitro data of patients. 
Patient Ag-density1 ID502 
No. (Mol./cellxlO-3) (M) 
1. 
2 . 
3 . 
4 . 
5. 
6. 
7. 
8. 
9. 
10 . 
1 1 . 
1 2 . 
21 
45 
85 
9 
85 
29 
118 
39 
74 
250 
87 
30 
1 0 - 9 
4 χ 1 0 - 1 0 
Ю -
1 1 
ND-
4 Х І 0 - 1 1 
2 x l 0 - 1 0 
З х Ю -
1 1 
З х Ю -
1 0 
1 . 5 X 1 0 - 1 1 
Ю -
1 1 
7 х 1 0 - 1 2 
Ю -
1 0 
1Antigen density of CD7 on the malignant cells of the 
patients as measured by 12:5l-WTi expressed in average number 
of molecules per cell. 2ID50 of WTl-ricin A in the presence 
of 6 mM NH4C1. 
*ND = not determined. 
RESULTS 
Cytotoxicity of WTl-ricin A to malignant Τ cells in vitro 
The cytotoxic potency of WTl-ricin A in the presence of 6 mM NH4CI was 
tested on the malignant cells of eleven out of twelve patients and 
expressed as dose required for 50% reduction of the protein synthesis 
(ID50). Malignant cells before initial therapy of patient 4 were not 
available for cytotoxicity studies. Protein synthesis was inhibited 
mainly depending on antigen density of CD7 on the cell surface (Table 
2). The average antigen density varied individually from 9000 to 250,000 
molecules per cell. As described previously, a strong correlation was 
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found between cytotoxicity and antigen density of CD7 (15). Malignant 
cells from patients with C-ALL and B-ALL without CD7 expression were 
used as controls. 
Effect of WTl-ricin A on hematopoietic progenitors 
The cytotoxicity of WTl-ricin A with or without NH4C1 to hematopoietic 
progenitors was determined by means of clonogenic assays. Cells were 
incubated with 10-e M WTl-ricin A, the dose used to treat large amounts 
of bone marrow. In comparison with untreated cells no influence of IT 
treatment in the presence of 6 mM NH4C1 was found on the plating 
efficiency Of CFU-GM (97 + 11%), CFU-GEMM (101 + 11%) and BFU-E (94 + 
10%) as determined in 5 independent experiments. 
Purging of bone marrow 
Low density marrow cells (d<1.070 g/ml) were incubated with lû-e M WTl-
ricin A in the presence of 6 mM NH4C1. This resulted in a slight 
reduction of nucleated cells (mean reduction 10%), CFU-GM and BFU-E 
(Table 3), that was probably not caused by cytotoxicity of the IT but 
largely due to the procedure itself. Patients received a mean cell dose 
per kg of 7.5 + 2.7 χ IO7 (range 4.5 to 13.4 χ IO"7) nucleated cells, 
11.2 + 9.5 χ 10* (range 1.9 to 37.6 χ 10*) CFU-GM and 17.2 + 11.7 χ 10* 
(range 3.7 to 42.9 χ 10*) BFU-E. 
Hematologic engraftment 
All patients engrafted after reinfusion of WTl-ricin A purged bone 
marrow. The mean day of recovery of leukocyte count to >109/l was day 
17.1 + 5.1 (median: 15.5; range 9 to 25 days) (Fig 1, Table 4). After 
recovery of leukocytes to >1.0xl09/l patient 6 was treated with 
ganciclovir, fluconazole and flucytosine because of the suspicion of CMV 
infection and a proven Candidemia. Subsequently leukocyte count dropped 
and the patient died in aplasia. Platelet recovery (>50xl04/l), was 
delayed in 3 patients (patients 8, 10 and 11) and was not évaluable in 2 
(patients 6 and 9). The median recovery occurred on day 38 (range day 14 
through 270). No relation was found between the state of disease, 
neither the number of reinfused hematopoietic progenitor cells (CFU-GM 
and BFU-E) nor the day of engraftment. 
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Table 3. Recovery after in vitro bone marrow purging. 
WBC CFU-GM BFU-E 
Patient Before IT After IT Before IT After IT Before IT After IT 
No. (xlO-9) (xlO-9) (xlO-6) (xlO-6) (xlO-6) (xlO-6) 
1. 
2 . 
3 . 
4 . 
5 . 
6. 
7. 
8. 
9 . 
10. 
1 1 . 
12 . 
3 .65 
6 .64 
4 . 0 1 
9 .80 
2 .90 
3 .90 
2 .80 
5 .65 
4 .85 
6 .54 
4 .60 
9 .80 
3 . 1 2 
5 .60 
3 . 6 0 
9 .00 
2 .80 
3 .30 
2 .20 
5 .65 
3 . 9 1 
5 .76 
4 .50 
9 . 4 0 
9 .5 
15 .0 
4 .6 
2 4 . 2 
3 .5 
2 . 2 
2 . 3 
31 .4 
4 .6 
3 .6 
3 .6 
6 . 4 
4 .8 
1 2 . 5 
3 . 2 
1 4 . 7 
3 . 5 
1 .2 
2 . 4 
2 4 . 1 
4 .6 
2 . 3 
3 . 2 
4 .6 
6 .7 
2 4 . 8 
1 2 . 0 
28 .6 
9 . 4 
2 . 3 
5 . 3 
3 9 . 0 
15 .6 
8 .8 
6 .7 
6 . 4 
4 .5 
23 .5 
9 .6 
14 .7 
9 . 1 
2 . 3 
4 . 2 
27 .5 
8 . 4 
5 . 1 
6 .7 
6 . 4 
X+SD 5.43+2.39 4.90+2.32 9.2+9.5 6.8+6.8 13.8+11.2 10.2+7.9 
Range 2.8-9.8 2.2-9.4 2.2-31.4 1.2-24.1 2.3-39.0 2.3-27.5 
¡-P<0.0025-1* |-P<0.025—¡ ¡-P<0.0125-¡ 
Evaluation of recovery after incubation of the bone marrow from 
patients with WTl-ricin A and NH4C1. WBC, white blood cells. 
'Correlation determined by the matched pair t-test. 
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Table 4. Clinical data after ΑΒΜΓ. 
Patient 
No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
Diagnosis 
Before Авмг 
T-ALL; CRI 
T-ALL; CRI 
T-ALL; CRI 
T-ALL; CRI 
T-ALL; CR2 
T-ALL; CRI 
T-ALL; CR3 
T-LL ЗА; CRI 
T-LL 4A; CR3 
T-LL 4A; CR3 
T-LL 4A; CRI 
T-LL ЗА; CRI 
Engraftment* 
WBC PLT 
(days) 
14 
17 
14 
9 
21 
13 
14 
13 
20 
25 
21 
25 
22 
32 
38 
14 
38 
NE" 
40 
180 
NE 
270 
>210 
60 
Status After 
ABMT 
Died after 7 mths in 
relapse (6 mths post-ABMT). 
Alive and CR, >44 mths. 
Alive and CR, >36 mths. 
Died after 7 mths in 
relapse (6 mths post-ABMT). 
Alive and relapse (5 mths 
post-ABMT), >11 mths. 
Died after 51 days by 
Candida and CMV. 
Alive and relapse (5 mths 
post-ABMT), >8 mths. 
Alive and CR, >40 mths. 
Died after 61 days by 
Strept. viridans and CMV. 
Alive and CR, >22 mths. 
Alive and CR, >7 mths. 
Alive and CR, >3 mths. 
ABMT, autologous bone marrow transplantation; CR, complete remission; 
T-ALL, acute T-cell lymphoblastic leukemia; T-LL, T-cell lymphoblastic 
lymphoma. 
•Recovery of leukocyte (WBC) counts to >109/1 and platelet counts to 
>50xl0Vl in days after ABMT. 
**Not évaluable. 
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Fig. 1. Recovery of leukocytes to >109/1 after autologous bone marrow 
transplantation. 
Survival 
Clinical data of survival after ABMT are shown in Table 4. Eight of the 
12 patients treated for T-ALL and T-LL are alive; two of them (patients 
5 and 7) relapsed within 5 months after ABMT in CR2 and CR3. Six 
patients are still in CR (3', 7*, 22*, 36*, 40*, 44* months). Four 
patients have died; 2 patients died 1 month after recurrence of 
leukemia, 1 patient died by a Candida and CMV infection (patient 6), 
and 1 patient by streptococcus viridans and CMV infection (patient 9). 
The calculated overall survival at 3 years is 64.8% and the 
probability of relapse free survival is 55.6% (Fig 2). The four 
relapses were found in patients treated for T-ALL: 2 of these patients 
(l and 4) had a low CD7 expression on their malignant cells. The other 
two patients were transplanted in CR2 and CR3 respectively. In the 
group of T-LL patients 4 of the 5 patients are alive and disease free 3, 
7, 22 and 40 months after ΑΒΙΪΓ. 
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Fig. 2. Kaplan-Meier estimate of the probability of actuarial 
relapse rate (—) and overall survival (...) of 12 patients 
with T-ALL or T-LL after autologous transplantation with WT1-
ricin A purged bone marrow. Vertical marks represent surviving 
patients (|). 
Immmologic recovery 
The patients who survived more than l year were followed for their 
hematologic and immunologic recovery (Table 5). Leukocyte counts 
normalized more than 6 months after ΑΒΜΓ, partly due to a longlasting 
granulocytopenia, whereas lymphocytes and monocytes achieved normal 
levels within 1 month. The immunologic recovery was delayed for at least 
1 year as determined by flow cytometric analysis of the lymphocyte 
phenotypes. СОЗ* and CD5* cells returned to normal levels within l 
months after АВМГ. However, the T4/T8-ratio was reversed for more than 6 
months and did not return to normal levels for at least l year. This 
decreased T4/T8-ratio was due to a low number of CD4* cells whereas CD8* 
cells returned to normal levels within 1 month. The number of CD7* cells 
did not reach normal values for at least l year. The functional recovery 
was tested by responsiveness to mitogens compared to normal individuals 
(Table 6). τ cells hardly responded to mitogens in the first 3 months, 
but returned to normal within 1 year after ΆΒΜΤ. 
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Table 5. Hematologic and immunologic recovery in patients who survived 
more than 1 year after ABMT. 
Months after ABMT 
12 
Leukocyte 
Lymphocyte 
Monocyte 
Granulocyte 
CDl 
CD3 
CD4 
CD5 
CD7 
CD8 
anti-B cell 
1.8+1.0 
0.73+0.30 
(42+11)-
0.23+0.20 
(12+6) 
0.76+0.50 
(42+14) 
0.02+0.01 
(3+2) 
0.68+0.35 
(78+9) 
0.28+0.09 
(37+10) 
0.52+0.29 
(63+18) 
0.12+0.01 
(18+10) 
0.43+0.28 
(47+11) 
0.08+0.06 
(9+9) 
2.5+1.3 
0.96+0.56 
(37+8) 
0.23+0.14 
(10+5) 
1.31+0.80 
(47+8) 
<0.01 
(<1) 
0.52+0.30 
(76+11) 
0.18+0.05 
(28+14) 
0.41+0.25 
(59+14) 
0.23+0.12 
(33+2) 
0.35+0.21 
(50+10) 
0.05+0.03 
(8+2) 
3.8+1.4 
0.95+0.57 
(26+12) 
0.33+0.11 
(9+3) 
2.40+0.98 
(64+11) 
<0.01 
(<1) 
0.64+0.38 
(85+9) 
0.21+0.04 
(32+19) 
0.64+0.38 
(74+6) 
0.29+0.19 
(48+13) 
0.34+0.21 
(39+3) 
0.09+0.06 
(7+5) 
4.8+1.4 
1.37+0.68 
(27+15) 
0.49+0.32 
(9+6) 
2.89+0.87 
(62+19) 
<0.01 
(<1) 
0.88+0.50 
(75+6) 
0.45+0.23 
(41+10) 
0.85+0.50 
(73+7) 
0.67+0.70 
(47+29) 
0.42+0.25 
(37+6) 
0.15+0.08 
(9+6) 
Values are expressed as mean number of cells xlO-9 + standard deviation. 
'Percentage of cells between parentheses. 
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Table 6. Functional recovery of lymphocytes in patients after 
ABMT. 
Months after ΑΒΜΓ 
1 3 6 12 
PHA 3+3 14+2 42+10 101+11 
Con A 2+3 8+6 41+27 97+9 
Values are expressed as mean percentage of -""H-thymidine 
incorporation by cells of normal individuals + standard 
deviation of 5 measurements. Average incorporation by 
lymphocytes of five normal individuals was 37,104 + 1441 cpm 
after PHA stimulation and 26,691 + 2608 cpm after Con A 
stimulation. 
DISCUSSIOW 
The first clinical results of ABMT after in vitro bone marrow purging 
with the anti-T cell IT, WTl-ricin A, are promising. All patients, 7 
with T-ALL and 5 with T-LL, had a bad prognosis at time of diagnosis 
(36). Although MoAbs with complement lysis are most commonly used for 
purging, ITs appear often more efficient in cell killing (28,29). 
Previously we demonstrated that WTl-ricin A in the presence of 6 mM 
ammonium chloride induces more than 6-logs kill of the malignant Τ cell 
line 'СЕМ' (15). СЕМ cells express intermediate amounts of CD7 
comparable to the CD7 density on malignant Τ cells of most patients. In 
vitro experiments showed that the cytotoxic efficacy of WTl-ricin A is 
highly related to the antigen density of CD7 on the malignant cell 
surface, which may imply effective reduction of the residual leukemic 
cells in the bone marrow of most patients. 
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A prolonged purging procedure of bone marrow with IT may be harmful 
to the hematopoietic stem cells. We have chosen for an intermediate 
incubation period of 16 hrs based on kinetics of cytotoxicity and 
internalization of cell bound IT (15). In our studies we showed that 
WTl-ricin A is continuously internalized in target cells coinciding with 
increasing cytotoxicity. In this and in other studies (26), no 
cytotoxicity of IT to hematopoietic precursors was found after 24 hrs 
incubation. This contrasts with the effects of cytostatic drugs when 
used in bone marrow purging (14,27). Bone marrow purging with 
ITS resulted in a slight reduction of hematopoietic precursors probably 
caused by intensive manipulation of the marrow. 
All patients in this study showed a fast engraftment of the bone 
marrow as monitored by the leukocyte counts >109/1 (median day 
15.5). The marrow recoveries were rapid compared to previous reports of 
nonpurged and otherwise purged autologous bone marrow (4,5,9,14,30,31), 
and comparable with the results of syngeneic marrow engraftment (32). 
These results provide evidence that sufficient hematopoietic precursor 
cells were present in the graft and survived the WTl-ricin A purging. In 
contrast the platelet recovery to 50xl09/l was strongly delayed in 3 
patients. The same phenomenon was observed in other studies (3,5,14,30). 
Although the number of lymphocytes (CD3- and CD5*) attained normal 
levels within one month the immunologic recovery appeared delayed for 
almost one year. CD7* cells remained low for at least 6 months. Data of 
de Gast et al (39), suggesting that the recovery of Τ cell subsets is 
mainly due to the proliferation of mature Τ cells in the graft, may be 
an explanation for this observation. No Τ cells with an immature 
phenotype (coi) were detected after l month. Functional recovery, as 
measured with response to mitogens, remained low for almost one year. 
This may be due to a defective T-helper function as observed by Armitage 
et al (40) resulting in a decreased T4/T8-ratio. The delayed immunologic 
recovery appeared not to be induced by the WTl-ricin A treatment because 
other investigators have found similar results in ABMT with other 
purging procedures or even without purging (30,40,41) and in allogeneic 
BMT (42). 
From the seven patients with T-ALL in the current study four 
patients relapsed whereas from the 5 patients with T-LL none relapsed. 
Whether the recurrence of leukemia was caused by residual leukemic cells 
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in the patient or in the bone marrow graft cannot be determined. Both 
mechanisms may play a role since two of the relapsed patients had a low 
CD7 expression on the malignant cells and otherwise T-ALL with a low CD7 
expression are less sensitive to high dose chemoradiotherapy. 
Determination of the CD7 expression on the malignant cells of patients 
who relapsed after ΑΒΜΓ showed no change in antigen density or antigen 
heterogeneity, suggesting that the recurrent leukemic cells were not an 
antigen negative selected population. Moreover, the cytotoxicity of WT1-
ricin A to these cells appeared not to be changed (data not shown). 
This contrasts with data of Thorpe et al. (33) who showed that surviving 
cells after IT treatment were resistent to the IT. Antigen density of 
the malignant cells of the other two relapsed patients, who were 
transplanted in CR2 and CR3, was high. Residual leukemic cells in these 
patients seem more likely the cause of relapse. Our results suggest that 
for an effective purging only leukemias with high antigen density on the 
cell surface should be selected. This may decrease the high relapse rate 
reported in most ΑΒΜΓ studies with immunologic purged bone marrow 
(31,34,35). Besides the state of disease influences the outcome of ΆΒΜΤ. 
Statistical evaluation of survival after ABMT is virtually 
impossible because of the low number of patients and the heterogeneic 
group of diseases. In the group of patients transplanted for T-ALL (7 
patients) the survival was 57% , 43% remained in CR, which is comparable 
with data of Gorin et al (1). The survival is higher than found by 
Kersey et al (34). In the group of T-LL none of the patients relapsed, 
but 1 patient died due to a nonleukemic complication. Although this 
group is too small for statistical analysis our results seem similar to 
those of others obtained in lymphoblastic lymphoma (3,4). 
The advantage of bone marrow purging is difficult to assess due to 
the various methods used for marrow purging and the lack of studies with 
large numbers of patients. Gorin et al (38) demonstrated by analysis of 
125 patients with ALL in first CR that, although no statistically 
significant advantage for purging exists, patients who received purged 
bone marrow had a higher percentage of disease free survival in 3 years 
(58%) than patients with nonpurged bone marrow (30%). 
We conclude that purging of bone marrow with WTl-ricin A prior to 
ABMT is a safe therapeutic option. It may be the treatment of choice for 
patients with high risk Τ cell malignancies. 
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C m V F T E R V 
CONCLUDING RíMABKS. 
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1. CCKCLUSICNS 
Ricin Α-chain immunotoxins (ITs) are very effective in eliminating 
malignant and normal Τ cells in bone marrow grafts. This is achieved by 
coupling target specific monoclonal antibodies (MoAbs) to the cytotoxic 
ricin Α-chain. ITs compete with and are often superior to other methods 
of elimination due to their specific cytotoxicity. However, not all 
hybrids of MoAb and toxin are suitable as IT. In this thesis the factors 
which determine the cytotoxicity and the clinical use of ricin A-chain 
ITs are investigated. 
ITs have to be internalized into the target cell in order to exert their 
cytotoxic action. The number of internalized molecules rather than the 
antigen density on the cell surface determines the cytotoxicity. 
Antigens which do not internalize the IT are not suitable as target for 
ITs. Moreover the intracellular transport of the ricin A is important 
for the cytotoxic efficacy and varies from one type of cell to another. 
ITs directed against CD3, CD5 and CD7 are rapidly internalized and 
have highly cytotoxic efficacy to both malignant and normal τ cells. 
Those directed against CD4 and CD8 are either not internalized or only 
to a small extent and therefore exert a low cytotoxic effect. 
The susceptibility of target Τ cells appears to be related to the 
state of activation: the susceptibility of nonproliferating normal Τ 
cells is lower than that of Τ cell lines, while PHA-stimulated Τ cells 
are effectively inhibited. The increased susceptibility of stimulated τ 
cells appears to be related to cell activity rather than antigen 
density. 
Lysosomotropic agents such as ammonium chloride strongly enhance the 
cytotoxicity of ricin Α-chain ITs depending on the target antigen. Ш
Л
С1 
causes a delay in transport of ricin A from endosóme to the lysosome and 
increases the pH of lysosomes to suboptimal values resulting in a 
decreased destruction of ricin A molecules by lysosomal enzymes. 
Ammonium chloride in a concentration of 20 mM greatly enhances the 
cytotoxicity of unstimulated Τ cells in vitro. The degree of T-
lymphocyte depletion from human bone marrow grafts is sufficient to 
prevent GVHD after allogeneic transplantation. This suggests that higher 
intracellular concentrations of ricin A can overcome the lower suscep-
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tibility of resting normal Τ cells. 
Although the τ cell population can be eliminated by the combination 
of anti-CD3, anti-CD5 and anti-CD7 MoAbs plus complement, ITs in the 
presence of 20 mM NH4Cl appear to be more effective than complement 
treatment. Extensive Τ cell depletion of the graft, however, may 
increase the risk of a delayed reconstitution or even rejection of donor 
marrow after allogeneic bone marrow transplantation (ΒΜΓ) ; besides the 
graft-versus-leukemia (GVL) effect may be compromised. Therefore 
elimination of subpopulations without simultaneous loss of the GVL 
potential may be a more reasonable approach. Selective elimination 
without loss of NK-activity can be effectively obtained with anti-CD4 
and anti-CD8 with complement. The appropriate ITs, however, are 
ineffective due to the low internalization of CD4 and CD8 antigens. The 
natural killer (NK) activity is little influenced by MoAbs directed 
against CD3 and CD5 with complement or as ITs, whereas anti-CD7 MoAbs 
strongly decrease the NK-activity. Therefore a combination of anti-CD3 
and anti-CD5 MoAbs with complement or as ITs 15 recommended in order to 
eliminate Τ cells in marrow grafts. 
Malignant Τ cells are, in contrast to normal resting Τ cells, very 
sensitive to ITs and as such can be compared to Τ cell lines. These can 
be used to mimic the killing potency of ITs to malignant Τ cells in bone 
marrow. At present exact assessment of the elimination of malignant 
cells is not feasible due to the lack of a suitable and reproducible 
clonogenic assay. 
ITs directed against the CD7 antigen are very suitable for the 
purging of bone marrow contaminated with acute Τ lymphoblastic leukemia 
or lymphoma cells because: a. the appropriate antigen is expressed in 
high quantities in almost all cases of T-ALL or T-LL, b. the IT is 
continuously internalized emphazising the importance of prolonged 
incubation for elimination even of cells with a low antigen density, с 
protein synthesis of malignant Τ cells is strongly inhibited by anti-CD7 
IT, and d. the viability of a malignant Τ cell line with an intermediate 
CD7 density is reduced by more than 6-logs after incubation with IT. 
Bone marrow intended for reinfusion can be safely incubated with 
ricin Α-chain ITs without significant loss of hematopoietic progenitor 
cells. The engraftment and hematologic reconstitution are not delayed 
when compared with reinfusion data of nonpurged bone marrow. Although 
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the results of autologous bone marrow transplantation after purging with 
anti-CD7 IT are promising at present no definitive conclusion can be 
drawn about its efficacy in comparison with nonpurged bone marrow due 
to the limited size of the treated patient group. 
2. KUTUHE PERSPECTIVES 
At present some ITs can be used for the in vitro elimination of 
malignant cells present in auto-grafts and of normal Τ cells in donor 
bone marrow. But as long as complete elimination of contaminating 
malignant cells cannot be guaranteed, investigations must focus on 
improving the cytotoxicity of ITs. Variation in toxins or coupling 
reagents may further improve the cytotoxicity. Moreover, a balanced 
cocktail of ITs, varying in toxins or MoAbs, may be the solution to the 
heterogeneous expression of antigens. Biological response modifiers 
(BRMs), such as interleukin-2 and interferon-gamma, may play an 
important role by increasing the number of binding sites. BRMs may be 
used in combination with ITs or administered to the patient in vivo 
before bone marrow aspiration. 
At present 85% of the potential candidates for ΒΙΉ do not receive a 
transplant due to the lack of a histocompatible sibling and the 
increased risk of graft-versus-host disease (GVHD) and its related 
complications which are more pronounced with increasing age. Therefore 
BMTs with partly matched family donors or histocompatible unrelated 
donors in combination with effective Τ cell depletion, and a more 
stringent conditioning of the patient will increase the number of 
patients that may benefit from allogeneic BMT. Although GVHD may be 
prevented in BMT with highly Τ cell depleted bone marrow, the risk of 
graft rejection and relapse increases considerably. Whether GVHD and GVL 
are mediated by one or different subpopulations of lymphocytes is not 
known and requires further study. 
Apart from normal τ cells in allogeneic bone marrow grafts and 
contaminating malignant cells in autologous grafts, residual cells in 
the patient that are not killed by sublethal dose of chemoradiotherapy 
are the main cause of relapse. Anti-cancer drugs have a low differential 
cytotoxicity to resting malignant cells in comparison with normal cells. 
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rapidly than normal cells. The in vivo application of ITs will provide a 
significant advance in the treatment of residual disease due to the less 
nonspecific cytotoxicity of the IT and the killing potency to malignant 
cells in a less active stage. When it becomes possible to use ITs 
effectively, dangerous and expensive therapy like BMT may no longer be 
necessary. However, higher demands are made upon the quality of the ITs 
because enhancers of cytotoxicity, such as ammonium chloride, cannot be 
administered to the patient in sufficient quantities. In vivo use of 
ITs is hampered by instability of the MoAb-toxin complex and rapid 
clearance by the monocytic-phagocytotic system (MPS). The instability 
has been overcome with the modification of the coupling reagents, 
whereas the rapid clearance of ITs by the MPS can be largely overcome by 
deglycosylation of the mannose and fucose residues on the toxin. These 
induce a more effective anti-tumour agent because it is cleared from the 
blood more slowly and so has greater opportunity to localize within the 
tumor. 
On the other hand when in vivo application of ITs becomes feasible 
this may result in stronger immunosuppression by eliminating radioche-
motherapy-resistant normal τ cells in the patient. Thus the risk 
of allogeneic graft rejection due to remaining Τ cells in the patient 
after the conditioning treatment may diminish. 
Even solid tumors with a low blood-tissue barrier resistant to any 
other therapy may be treated with modified ITs. A large number of MoAbs 
directed against tumour cell specific antigens have been, and are being, 
developed. In combination with different toxins these MoAbs will result 
in a wide range of anti-tumour agents forming a new generation of 
cytostatics. In the next few years it will become more clear whether ITs 
are going to fulfil their potential and become a major weapon in the 
fight against cancer. 
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Allogeneic bone marrow transplantation (BMT) is increasingly used as 
alternative treatment for patients with leukemia or lymphoma that have a 
poor prognosis with conventional therapy. BMT allows substantial dose 
escalation (up to sublethal doses) since this treatment is followed by 
rescue with donor bone marrow. Graft-versus-host disease (GVHD), induced 
by immunocompetent Τ cells in the graft, is a major problem in BMT and 
restricts this treatment to HLA-identical siblings. Therefore an 
alternative to allogeneic BMT is rescue infusion with autologous bone 
marrow aspirated prior to high dose treatment. This marrow may contain 
residual malignant cells the reinfusion of which will result in a 
relapse of the disease. In the last few years many methods for purging 
of bone marrow have been developed but often these are too nonspecific 
or have low cytotoxicity. Monoclonal antibodies (MoAbs), directed 
against specific differentiation antigens present on malignant Τ cells, 
and conjugated to the cytotoxic Α-chain of the phytolectin ricin, appear 
to be highly specific cytotoxic immunotoxins (ITs) for the elimination 
of malignant Τ cells in autologous bone marrow as well as normal Τ cells 
in donor bone marrow. Ricin Α-chain is an irreversible inhibitor of 
protein synthesis and is only effective within the cell. In this thesis 
parameters determining the cytotoxicity of ITs to normal and malignant Τ 
cells and the clinical use of anti-T cell ITs are discussed. 
Internalization of ITs in the target cell is a prerequisite for the 
cytotoxic activity of the ricin A. Although one molecule penetrating 
into the cytosol can destroy a cell, high amounts of IT have to be 
internalized. Only antigens that have high internalization capacity are 
suitable as target for ITs. The density of such antigens on the cell 
surface determines the cytotoxicity of the ITs (Chapter 2). Moreover the 
cytotoxicity can be greatly enhanced by lysosomotropic agents like 
ammonium chloride depending on antigen and cell type. 
Anti-T cell ITs that are well internalized (ITs directed against 
CD3, CDS and CD7), separately or in a cocktail, hardly eliminated normal 
τ cells in bone marrow whereas human Τ cell lines were killed very 
effectively depending upon antigen density. After stimulation τ cells 
became sensitive to IT treatment suggesting that the metabolic state of 
the cell is an important factor. However, ITs in the presence of 20 mM 
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ШЛ
С 1 killed larger number of resting Τ cells exceeding the elimination 
obtained with free MoAbs plus complement. Complete elimination of Τ 
lymphocytes in bone marrow, although overcoming GVHD, may result in a 
high rate of rejection and relapse after ВИГ. Specific depletion of Τ 
cell subpopulations therefore appear to be a more suitable approach. 
MoAbs directed against helper/inducer or suppressor/cytotoxic Τ cell 
subpopulations {CD4 and CD8) are hardly internalized and can only 
effectively used to kill cells in combination with complement (Chapters 
3 and 4). 
In contrast to normal Τ cells, ITs inhibit the protein synthesis of 
malignant Τ cells and Τ cell lines to a similar extent. The highly 
cytotoxic IT WTl-ricin Ά (CD7) appears to be suitable for the 
elimination of malignant Τ cells in bone marrow intended for autologous 
reinfusion. In most cases of acute Τ cell leukemia or lymphoma, 
malignant cells express the CD7 antigen in high amounts on their cell 
membrane. Besides, WTl-ricin A is continuously internalized increasing 
the chance of eliminating cells with a lower CD7 expression. Because no 
suitable culture-system exists for malignant Τ cells, the exact amount 
of cell-killing was determined by a clonogenic assay of a Τ cell line 
that expresses CD7 comparable with malignant Τ cells of most, patients. 
Cell viability was reduced by more than 6-logs after incubation with the 
IT (Chapter 5). 
Autologous BMT after WTl-ricin A treatment of the marrow of 12 
patients is also described (Chapter 6). To our knowledge no other 
comparable numbers of transplantation of bone marrow purged by ricin A-
chain IT have been published. All patients repopulated rapidly after 
reinfusion and the hematologic reconstitution was not impaired, though 
the functional reconstitution of lymphocytes was delayed. This was not 
caused by the method of purging and no clinical side effects were 
observed. Although the follow up is short and the group of patients is 
still small, the results of these autologous BMT are promising. 
Therefore, ITs may contribute to an increase in the survival and quality 
of life of patients undergoing treatment for cancer. 
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Allogene beenmergtransplantatie (БМГ) wordt in toenemende mate toegepast 
als alternatieve behandeling bij patiënten met leukemie of maligne 
lymfoom, aangezien zij een slechte prognose hebben in geval van 
conventionele chemotherapie of bestraling. Voorafgaande aan de infusie 
van donorbeenmerg Jcunnen patiënten behandeld worden met aanzienlijk 
hogere doses radiochemotherapie, tot zelfs sublethale doses. Graft-
versus-host ziekte (omgekeerde afstotingsziekte, GVHZ), welke 
geïnduceerd wordt door immuuncompetente Τ cellen in het transplantaat, 
is een van de belangrijkste problemen na BOT. Daarom is deze behandeling 
nu nog beperkt tot transplantatie van weefsel-identiek beenmerg, in de 
praktijk afkomstig van een nauw verwante donor, meestal een broer of 
zuster. De konsequentie is dat bij maximaal 15% van de patiënten die in 
aanmerking komt voor BOT daadwerkelijk een transplantatie kan worden 
uitgevoerd. Een alternatief voor allogene BOT is reinfusie van autoloog 
beenmerg, afgenomen in remissie-fase. Dit beenmerg kan echter nog 
residuale maligne cellen bevatten welke na reinfusie een recidief kunnen 
veroorzaken. Verwijderen van deze maligne cellen is een voorwaarde wil 
autologe reinfusie werkelijk succesvol zijn. 
In de laatste jaren zijn talrijke methoden ontwikkeld om maligne 
cellen uit beenmerg te verwijderen. Deze zijn echter dikwijls aspecifiek 
of hebben een lage effectiviteit. Monoclonale antilichamen (MoAbs), 
gericht tegen specifieke differentiatie antigenen op maligne T-cellen en 
geconjugeerd met de cytotoxische A-keten van de fytolectine ricine, 
genaamd immunotoxines (ITs), hebben een specifieke en bij juiste keuze 
een sterke cytotoxiciteit. Ricine A is een irreversibele remmer van de 
eiwitsynthese en is alleen effectief in het cytoplasma van de cel. 
Gebleken is dat ITs zeer geschikt zijn voor de eliminatie van maligne T-
cellen uit autoloog beenmerg enerzijds, en normale T-cellen uit donor-
beenmerg anderzijds. 
In dit proefschrift is het onderzoek beschreven van parameters 
die de cytotoxiciteit van ITs voor maligne en normale T-cellen bepalen 
en de klinische ex vivo toepassing van anti-T-cel ITs. De receptor-
afhankelijke endocytose van het IT is een voorwaarde voor de activiteit 
van ricine A. Hoewel één molekuul, na doorgedrongen te zijn in het 
cytoplasma, voldoende is om de targetcel te vernietigen, moet door de 
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hoge intracellulaire afbraak een grote hoeveelheid ITs geïnternaliseerd 
worden. Daarom zijn alleen antigenen die een hoge intemalisatie 
capaciteit bezitten geschikt als target. De dichtheid van deze antigenen 
op het celmembraan bepaalt de cytotoxiciteit van het IT (Hoofdstuk 2). 
Bovendien kan de cytotoxiciteit sterk verhoogd worden door lysosomotrofe 
agentia zoals ammonium chloride, dit is echter afhankelijk van antigeen 
en celtype. Ammonium chloride verhoogt o.a. de lysosomale pH waardoor de 
lysosomale enzymactiviteit wordt verlaagd en minder ricin A wordt 
afgebroken. 
Anti-T-cel ITs welke in sterke mate geïnternaliseerd worden (ITs 
gericht tegen CD3, CD5 enCD7), afzonderlijk of in een cocktail, 
reduceren nauwelijks het aantal normale T-cellen in beenmergaspiraten, 
terwijl humane T-cellijnen, afhankelijk van antigeen dichtheid, zeer 
effectief gedood kunnen worden. Normale rustende T-cellen worden echter 
gevoelig voor IT behandeling na stimulatie tot metabole activiteit met 
phytohaemagglutinine (PHA) suggererend dat het activatiestadium van de 
cel een belangrijke rol speelt. Toch kunnen ook rustende T-cellen 
grotendeels worden geëlimineerd door ITs indien deze worden aangeboden 
in aanwezigheid van 20 mM ammonium chloride. Deze eliminatie overtreft 
de depletie van T-cellen zoals verkregen na incubatie met MoAbs in 
combinatie met konijnen complement. 
Totale eliminatie van normale T-lymfocyten uit donorbeenmerg voor-
komt het optreden, van GVHZ na BMT maar verhoogt de kans op een rejectie 
van het transplantaat of een recidief van de maligniteit. Een specifieke 
en gedoseerde depletie van T-cel subpopulaties lijkt daarom een betere 
benadering voor de preventie van GVHZ omdat op deze wijze cellen die een 
anti-leukemisch effect bezitten gespaard kunnen worden. Anti-CD7 ITs 
lijken hiervoor minder geschikt omdat het CD7-antigeen ook voorkomt op 
cellen met een anti-leukemische activiteit. MoAbs gericht tegen 
helper/inducer (CD4*) of suppressor/cytotoxische (CDSM T-cel sub-
populaties worden nauwelijks geïnternaliseerd en zijn alleen effectief 
in combinatie met complement (Hoofdstukken 3 en 4). 
In tegenstelling tot het geringe effect van ITs op normale Τ cellen 
wordt de eiwitsynthese van maligne T-cellen en T-cellijnen in sterke 
mate geremd. Het zeer effectieve anti-CD7 IT, WTl-ricine A, blijkt 
daarom wel geschikt te zijn voor de eliminatie van maligne T-cellen uit 
beenmerg bestemd voor autologe reinfusie. Bij de meeste patiënten met 
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acute T-cel leukemie of lymfoom komt het CDV-antigeen in grote 
concentratie voor op het celmembraan van de maligne T-cel. Daarnaast 
wordt het CD7-WTl-ricine A-complex continu geïnternaliseerd waardoor de 
kans op eliminatie van cellen met een lagere CD7-expressie toeneemt. 
Omdat tot heden geen reproduceerbare methode ontwikkeld is voor de 
vermeerdering van maligne T-cellen in vitro, is de eliminatie van dit 
celtype bepaald met behulp van een donogene assay op een T-cellijn. De 
CD7-expressie op deze cellijn was vergelijkbaar met die op maligne 
cellen van de meeste patiënten. Het aantal viabele donogene cellen werd 
door incubatie met WTl-ricine A met meer dan 6-log gereduceerd 
(Hoofdstuk 5). 
Twaalf patiënten hebben een autologe reinfusie ondergaan na 
purgering van hun beenmerg met WTl-ricine A (Hoofdstuk 6). De hematolo-
gische reconstitutie was niet nadelig beïnvloed, maar de functionele 
reconstitutie was vertraagd. Deze vertraging is met veroorzaakt door de 
methode van celdepletie. Klinische neven-effecten zijn niet waargenomen. 
Uit de literatuur zijn momenteel geen waarnemingen bekend over een 
vergelijkbaar aantal transplantaties na beenmergpurgering met ricine 
A IT. Alle patiënten repopuleerden snel na de reinfusie. Hoewel de 
periode van controle na вмт kort is en de serie patiënten klein, zijn de 
resultaten van deze autologe ВМТ positief te noemen. iTs lijken daarom 
bij te dragen aan de verbetering van de levensperspectieven van bepaalde 
groepen patiënten die een anti-kanker therapie moeten ondergaan. 
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STELUHCTH 
1. Het cytotoxisch effect van immunotoxines hangt sterker af van de 
mate van intemalisatie van het relevante targetantigeen-immuno-
toxinecomplex, dan van de antigeendichtheid op het celmembraan. 
(dit proefschrift) 
2. Bij gebrek aan representatieve en reproduceerbare donogene assays 
voor maligne cellen, bieden cellijnen een redelijk alternatief voor 
de bestudering van de werking van cytotoxische agentia op donogene 
prolifererende cellen. (dit proefschrift) 
3. Zowel normale als maligne T-cellen kunnen ex vivo effectief 
verwijderd worden uit beermergaspiraten met immunotoxines welke in 
voldoende mate geïnternaliseerd worden. (dit proefschrift) 
4. De gevoeligheid van maligne T-cellen voor immunotoxines is groter 
dan die van normale T-cellen. (dit proefschrift) 
5. De lage gevoeligheid van normale T-cellen voor immunotoxines wordt 
niet veroorzaakt door een verhoogde lysosomale activiteit. 
(eigen waarneming) 
6. Hoewel het belang voor de in vivo functie van een groot aantal 
typen membraanmoleculen op T-cellen niet bekend is, bieden deze in 
principe wel een aangrijpingspunt om selectief normale en/of 
maligne T-celpopulaties met een heterogene antigeen-expressie te 
elimineren door deze moleculen als target voor immunotoxines te 
gebruiken. 
7. De verhoogde kans op een recidief na een allogene beenmergtrans-
plantatie met T-cel gedepleteerd beenmerg zou verminderd kunnen 
worden wanneer de eliminatie beperkt wordt tot specifieke T-cel 
subpopulaties, waarbij de cellen met "naturai killer" activiteit in 
het beenmerg aanwezig blijven. 
8. De neiging om risicodragende subsidieaanvragen een lager waarde-
ringscijfer toe te kermen, werkt in de hand dat subsidies worden 
toegekend aan onderzoek waarvan de uitslag al bij voorbaat 
vaststaat. 
9. Bezuinigingen op researchgelden leiden tot vervuiling van de 
literatuur daar de drang tot publiceren van preliminaire resultaten 
verhoogd wordt. 
10. De uitspraak "verder onderzoek is noodzakelijk" betekent in de 
praktijk een verwijzing naar een volgende publicatie. 
11. Epstein-Barr virus (EBV) kan naast B-lymfocyten eveneens T-cellen 
infecteren en de groei dereguleren. (Kikuta et al. Nature 1988, 
333, 455) 
12. De "magie bullet" waar Paul Ehrlich van droomde (in: F. Himmelweit, 
Pergamon, New York, 1960; 1) blijkt in vivo vaak een "dum-dum 
kogel" effect te bewerkstelligen. 
13. De mededeling door sprekers dat zij beperkt worden in hun 
voordracht door gebrek aan tijd kan gezien worden als promotie van 
eigen werk. 
14. Met de introductie van automatisch openende deuren blijkt de 
beleefdheid om voor anderen een deur open te houden te zijn 
vervallen. (eigen waarneming) 
15. Een computerbestand is sneller en met meer zekerheid te purgeren 
dan beenmerg! 
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